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Abstract 
 
The αVβ5 integrin is a member of integrin family that binds to different ligands such as 
vitronectin, fibronectin and soluble CD23 in order to mediate different biological 
responses such as cell growth, adhesion and metastasis. It is expressed  by B cell 
precursors and by different acute lymphocytic leukaemia cell lines such as SMS-SB 
cells. This thesis is an attempt to explain how the sCD23- αVβ5 integrin interaction 
stimulates SMS-SB cell growth and to study the role of  the αVβ5 integrin and other 
receptors such as PDGF receptor and CXCR4 in B cell development in the bone 
marrow. The maturation and differentiation of B-cells occur due to several factors that 
impact on gene expression in its development program. This program is divided into 
two main phases, the antigen-independent B-cell development phase and antigen-
dependent B-cell development phase, respectively. The antigen - independent phase of 
B cell development starts from the pluripotent haemopoietic stem cell (PHSC) and 
progresses through several successive stages which are identified by somatic 
recombination and rearrangement of both heavy and light chain genes. 
Soluble CD23 and LP (a synthetic peptide derived from soluble CD23) significantly 
stimulate SMS-SB growth while a smaller growth stimulation is caused by either SDF1-
α or PDGFAB. There are different signalling targets involved in the αVβ5 integrin-
mediated proliferation due to its binding to either sCD23 or LP. These ligands enhance 
the association between the αVβ5 integrin and the PDGF receptor which promote the 
phosphorylation of both Jak2 and STAT5. Moreover, cell growth was reduced and the 
phosphorylation of Jak2 and STAT5 was also knocked down with using either PDGF 
receptor inhibitor (AG1295) or Jak2 inhibitor (AG490). 
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Both soluble CD23 and LP activate the STAT5-DNA binding and strongly increase its 
transcriptional activity. In addition, both ligands induce the phosphorylation of other 
different substrates such as STAT2, c-Src, c-yes and AMPKα2 which might be related 
to cell growth stimulation. 
 The αVβ5 integrin ligands also promote the phosphorylation of ERK1/2, p90RSK and 
activate a SRF transfected reporter gene. However, ERK1/2 and p90RSK 
phosphorylation was completely blocked by the specific MEK inhibitor (U0126). In 
similar context, SDF1-α stimulates the transcriptional activity of SRF but not STAT5 
while PDGFAB does the opposite. Finally, soluble CD23 induces the proliferation of 697 
and BAF03 which are other pre-B cell line models. 
These data suggest that the αVβ5 integrin-ligated ligands stimulate SMS-SB cell growth 
by promoting different signalling pathways, mainly Jak2/STAT5 and MEK/ERK1/2 
pathway.  
Further work is required to determine the role of STAT5, p90RSK, c-Src and SRF in 
stimulating either the proliferation or apoptosis that promoted by  the αVβ5 integrin-
sCD23 interaction and to investigate the relationship between the activation of these 
targets. 
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1  Introduction 
 
1.1 B Lymphocytes 
1.1.1  Introduction 
 
The immune system is divided into two major systems, the humoral and cell- mediated 
immune system. Both of these classes are  linked together such that each one works 
optimally with the other 1.  Cellular compartments of the immune system can be classified 
into two main groups based on their lineages; the myeloid lineage which includes 
monocytes, macrophages, erythrocytes, megakaryocytes, and the lymphocyte lineage 
which produces B or T lymphocytes 2. The B lymphocyte is one of the major members of 
the immune system which plays a key role in the humoral immune system due to its ability 
to produce and release a vast number of immunoglobulins after its activation and 
differentiation into a plasma cell. B refers to Bone marrow where the generation and 
maturation of B cells takes place in humans. B cells, like other cellular compartments of 
the immune system, are generated from hematopoietic  stem cells. The lineage of B-
lymphocytes begins in foetal liver and B-cell  lymphopoiesis takes place in bone marrow in 
all mature mammals 3. It is derived from the pluripotent haematopoietic stem cell (PHSC) 
similar to any other blood cellular compartments 3. The maturation and differentiation of 
B-cells occur due to several factors that impact on gene expression in its development 
program 3. This program is divided into two main phases, the antigen-independent B-cell 
development phase and antigen-dependent B-cell development phase, respectively 3. 
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1.1.2 Antigen-independent B-cell development phase 
 
The antigen - independent phase of B cell development occurs in the bone marrow,  
starting from the pluripotent haemopoietic stem cell (PHSC) and progresses through 
several successive stages 4. B-cell developmental stages in this phase are characterized by 
somatic recombination and rearrangement of both heavy and light chain genes 5. The 
earliest step of B-cell development in this phase starts with differentiation of the PHSC 
into lymphoid stem cells (LSC), which are also called CD34+ bipotential lymphoid stem 
cells 5. Under the effect of certain transcriptional factors such as PU.1, Ikaros and E2A, 
LSCs become either a T-cell precursor which is identified by expressing CD2 and CD7, or 
a B-cell precursor which is identified by expression of CD19 6,7,8,9. The first B lineage – 
committed progenitors are called pro-B cells and are characterized by the presence of both 
CD45R and CD43 on their plasma membrane outer surface (figure 1.1) 6. In addition, late 
pro – B cells are characterized by the presence of cytoplasmic heavy chain protein of the µ 
class as well as CD19 (figure 1.1) 6,7. Almost  all of these markers are Ig heavy chain  
rearrangement related  6,7. The process of Ig heavy chain rearrangement is completed by 
joining VH to DJH at the end of pro-B cell maturation stage which leads to expression of µ 
chain on the cell surface as a part of pre-B cell receptor (pre-BcR) which appears as a 
marker of the transition from pro-B cell to pre-B cell (figure 1.1) 10,11. During the early 
stages of pre-B cell maturation, cells are large and identified by CD43 down-regulation as 
well as Vpre-B /λ5 surrogate light chain expression (figure 1.1) 6,10. 
At this stage, cells undergo a rapid proliferation process which leads to increased µ chain 
expression on the outer plasma membrane surface 5. Consequently, the dramatic increase 
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of  proliferation increases the opportunity of µ chain attachment to IgL chains, which is 
essential for further maturation, signalling and processing 5.  
 
  
Figure 1.1 Antigen dependent B-cell development. B-cells are derived from a Pluripotent haematopoietic 
stem cell which is converted to a lymphoid stem cell (LSC). Due to the DH,JH locus rearrangement, the LSC 
is converted to early  pro B-cell stage which is characterized by CD19,CD45R and CD43 expression. At the 
late pro B-cell stage the cytosolic µ heavy chain starts to appear as a phenotypic reflection of VH-DH-JH 
rearrangement process. Consequently, these alterations lead to conversion of pro B-cell into Pre B-cell which 
seems  morophogically large and characterized by CD19, CD45R and µ heavy chain – light chains (as the 
Vpre-B /λ5 surrogate). These cells proliferate and convert to small pre B-cells which in turn convert to 
Immature B- cells which express IgM on their surface. The last stage of this process is called the mature B-
cell and expresses IgM and IgD and migrates to the secondary lymphoid organs such as spleen and germinal 
centres.            
 
In general, the Pre-B cell stage is characterized by the presence of several markers such as 
CD45R+ , CD43¯
  
and IgL locus re-arrangement during the small late pre-B cell stage 
(figure 1.1)  6. Light chain gene rearrangement and complete IgM expression on the cell 
surface are important markers that define the immature B cell stage 6,11. After that, 
immature B cells undergo further differentiation and other gene rearrangement processes 
which lead to expression of both IgM, IgD and CD23 as well as CD45R on the cell surface 
6,11
. The B cell is now ready to leave the bone marrow and migrate into peripheral 
lymphoid tissue such as spleen and lymph nodes 6,11.  
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1.1.3 Antigen-dependent B-cell development 
 
The lifespan of mature B-cells in the secondary lymphoid tissues and circulation system is 
between several weeks to several months and to maintain the quantity of B-cells in both 
systems the newly-developed B-cells are eventually replaced 12. 
In this phase, B-cell activation occurs by two different processes,  T - cell -  dependent and 
T-cell - independent development. In fact, the immune responses require both processes 12. 
B-cell activation starts by the binding of B-cell receptor (BcR) to the specific antigen either 
via cognate recognition and  T-cell help or through cross - linking of the BcR by antigens 
1,12
. T-cell independent development occurs without MHC class II- restricted  T-cell help 
and leads to a response to a small number of antigens 1.These thymus-independent antigens 
are resistant to degradation processes and can be classified into two categories depending 
on their mode of activation. The first category is  bacterial cell wall components which 
belong to Gram-negative bacteria and all of them are lipopolysaccharides, while the second 
category is large polysaccharide molecules. The activation of B cells by the first group 
requires high antigen concentrations. However, the second group can activate B cells by 
using non-cognate T-cell help  such as cytokines  1,12.   
In general, T-independent antigen stimulation occurs through several signal transduction 
molecules such as TNFα, CD19, HS1 protein, Lyn, IL-5Rα as well as lymphotoxin α. On 
the other hand, in the T- dependent antigen development process, B cells undergo 
proliferation, differentiation and activation by the interactions between T-cells and B-cells. 
These interactions require the help of T helper cells (TH) and sets of complementary 
cytokines 12.  
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1.1.4 The importance of non-lymphoid stromal cells of the 
bone marrow for B cell development 
 
Isolated stem cells cannot differentiate into B cells in culture unless grown in the presence 
of bone marrow stromal cells which  provide several important factors 11. One of these 
factors is the ability of stromal cells to provide specific adhesive contacts with the B cell 
during all developmental stages, using particular cell-adhesion molecules and ligands 11. 
Moreover, several essential soluble growth and differentiation factors are provided by 
stromal cells. Stem cell factor (SCF) is one of these factors which is mandatory for B cell 
development 11. SCF is a member of c – kit ligand family which interacts with a tyrosine 
kinase receptor on the outer membrane surface of B cell precursors 11. Another important 
factor is the chemokine CXCL12,  also called Stromal cell-derived factor 1 (SDF1), which 
stimulates the proliferation of both pro-B cells and pre-B cells, and is required for the 
maturation of B-cell precursors 11. In mice, both pro-B cells and pre-B cells require 
interleukin 7 (IL-7) produced by bone marrow stromal cells 12. In vitro, interleukin 7 shows 
an effective role in cellular proliferation, survival and development. However, in humans 
there is no clear evidence about the roles of  IL-7 in any of these processes 12. 
1.1.5 Disorders caused by defects during antigen –
independent B-cell development 
 
1.1.5.1 Primary immunodeficiency 
1.1.5.1.1  X- linked agammaglobulinaemia (XLA) : 
 
XLA is one of the primary immunodeficiency disorders and is caused by a Bruton’s 
tyrosine kinase (BTK) gene mutation 4. This mutation occurs in X-linked agammaglobulin 
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(XLA) and all XLA patients have a deficiency in the percentage of normal peripheral 
blood B cells as a result of blocking the transition of  pro- B cells to the large pre- B cells 
due to the mutation. BTK is a major player in signalling downstream of pre-BcR, as well 
as having a role in BcR activation, primarily by stimulating calcium flux 4. In fact, BTK 
gene mutations lead to changes either in BTK protein folding or stability 4. 
 
1.1.5.1.2 Common Variable Immunodeficiency (CVID) : 
 
Individuals with this disease exhibit a low level of plasma Ig and they are susceptible to 
infections as well as having a variable reduction in memory B cells, class switch 
recombination (CSR) and B cell activation 4. This disease is characterized by several 
mutations such as in the activated T cell stimulatory molecule ICOS, CD19 and  TNFα 
receptor 4. 
 
1.1.5.1.3 Hyper- IgM syndrome : 
 
Hyper-IgM syndromes are  humoral immunodeficiencies.  Patients who are suffering from 
this disease have elevated serum IgM and decreased IgD and IgA serum levels together 
with recurrent infections 13. This disease is characterized by several mutations and there are 
five types of it  defined so far. HIM-1 is the most common, being an X-linked mutation  in 
CD154 4. Furthermore, the defect of CD40 signalling is considered as the major reason for 
the disease development, because due to this defect B-cells do not recognise T-cells which 
blocks Ig class switch recombination (CSR) in B-cells 14. The second type is HIM-2, a very 
rare type, which is an autosomal recessive inherited syndrome 15. This type is characterized 
by  deficiency of Activation-Induced Cytidine Deaminase (AID) which in turn leads to a 
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CSR defect 16. HIM-3 is caused by mutation of the  CD40 gene as well as one of the 
Activation-Induced Cytidine Deaminase genes (AICDA) 16,17. The last two HIM-4 and 
HIM-5, are both CSR defects  but have different mutations to the others 17. 
1.1.5.2 Autoimmunity 
 
Within the B-cell lineage there are several checkpoints which control B- cell selection, 
both in the bone marrow and the peripheral lymphoid tissues 4. The activation or the 
inhibition of B-cells, which depends upon both T-cell stimulation and the B-cell itself, 
requires balance between the activating signals to protect our bodies from the invasive 
pathogens 18. On the other hand, the imbalance between those signals could lead to either 
massive infections or autoantibody production and autoimmunity as a result  18. 
Autoantibody production is believed to be a natural process of the adaptive immune 
response that arises as a consequence of the imbalance between the activating and the 
inhibiting signals, for example, in rheumatoid arthritis, an autoimmune disease 19. 
Recently, the contribution of B-cells to several autoimmune diseases in the human being 
has become clear 4,19. In this regards, the B-cell contributes to autoimmune diseases in 
different ways, for example by producing autoantibodies such as in systemic lupus 
erythematosus (SLE), by presenting autoantigen to T-cells or by producing  
proinflammatory cytokines 19,20.    
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1.1.5.3 Leukaemia and lymphomas  
 
Several haematological and immunological studies have shown both cytogenic and 
molecular genetic abnormalities in malignant B-lineage cells 4. In follicular lymphoma, the 
anti-apoptotic Bcl-2 gene is translocated to chromosome 14 and falls under the influence of 
the enhancer element (Eµ) of the Igh locus 21. In addition, clonal Ig gene rearrangements 
are implicated in Hodgkin’s lymphoma 22. The second part of this review will give more 
details about the acute lymphocytic leukaemias.  
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1.2 Leukaemia 
 
1.2.1 Introduction 
 
Leukaemia is a Greek term; Leukos means white or clear and heima means blood. In 
general, Leukaemia is a definition of  blood cancer which means an abnormal and 
uncontrolled  growth of blood cells in bone marrow 23. It occurs in either mature or 
immature cells 23. Generally, there are three major classes of blood cancer; leukaemia, 
lymphoma and multiple myeloma. Both leukaemia and lymphoma affect lymphoid cells 
but there are several essential pathological differences between them. Leukaemia usually 
occurs in bone marrow during the lymphoid cell maturation process, while lymphoma 
originates in lymphatic system causing enlargement the affected tissues  and is generally a 
solid tumour 24.  
There are four major types of leukaemia which are classified according to the cell type and 
mode of  progression : 
1. Acute lymphocytic leukaemia (ALL) occurs in either T or B lymphocytes. In this 
type of leukaemia,  the cells, mainly immature lymphocytes, grow rapidly 25. Most 
recorded cases are children but it is also affects adults 25. The cell line model used 
in this study is called SMS-SB cells which was established from the bone marrow 
of nine year-old girl suffering from acute lymphocytic leukaemia. These cells are 
B-cell precursors roughly between Pro-B cells and large pre-B cells. 
2. Chronic Lymphocytic leukaemia (CLL) occurs in either T or B lymphocytes 26. 
It is called chronic because cells grow slowly; the progression is different from 
patient to patient but generally takes months to years and the majority of affected 
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cells are mature B lymphocytes 26. Chronic leukaemia is common in older people 
but it is found in  different age groups 25. 
3. Acute myelogenous leukaemia (AML)  occurs in myeloid cells and it is common 
in adult males but can also occur in children and females 27. In this type of 
leukaemia, cells grow rapidly and the bone marrow becomes very congested. There 
are different subtypes of AML such as acute megakaryoblastic leukaemia, acute 
promyelocytic leukaemia and acute myeloblastic leukaemia 27. 
4. Chronic  myelogenous leukaemia (CML) occurs in myeloid cells, mainly  in 
adults and can occur in children though that is very rare. It is characterized by slow 
progression and there is one subtype of this leukaemia called chronic monocytic 
leukaemia 28. Clinically, 95% of diagnosed cases were associated with BCR/ABL 
chromosomal translocation (Philadelphia chromosome) 29. 
5. Other types of leukaemia; there are some other types of leukaemia such as Hairy 
cell leukaemia (HCL) which occurs mainly in adult males and is easy to treat, T-
cell prolymphocytic leukaemia (T-PLL) which affects mature T-cells and mainly 
in adults. This type of leukaemia is very rare, occurs in men more than woman and 
is very aggressive 25. Large granular lymphocytic leukaemia which  affects 
either Natural killer cells or T-cells, is very rare and not aggressive 25. Adult T-cell 
leukaemia is a viral infectious disease caused by HTLV. This virus infects CD4+T-
cells and makes them proliferate abnormally 25.       
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      1.2.2 Acute lymphocytic leukaemia (ALL) 
 
Acute lymphocytic leukaemia is a malignant disease occurring in lymphoid cell precursors  
and can affect either adults or children 30. Clinical statistics show that the most common 
cases arise between the ages of 2 to 5 years. In addition, there is a promising development 
of treatment where more than 80% of cases have been cured using different kinds of 
regimens containing vincristine, cyclophosphamide, doxorubicin or methotrexate which 
also depends on genotype, phenotype and risk assessment 31, 30.  
 
1.2.2.1 Acute lymphocytic leukaemia classification 
 
There are different systems to classify ALL according to different biological and clinical 
features. Clinically, the most common classification used is called French American 
British (FAB) system which classifies ALL according to a number of biological features 32 
,33
. The main purpose of this system is to simplify the selection of treatment procedures 
including the regimen components, dose and the treatment period. In this system, ALL is 
classified into three primary sub-types according to size and shape of the leukaemic cells 32 
,33
. 
L1 is the most common in children. Morphologically, lymphoblasts  are small with normal 
nuclear shape and are either T-cells or B-cells 34. 
L2 occurs in adults more than children. In this sub-type, the affected lymphoblasts are T-
cells or B-cells and they are immature and pleomorphic. Cells look large with cytogenetic 
and nuclear shape alterations 34.   
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L3 also called Burkitt’s leukaemia/lymphoma which represents the least percentage of 
recorded cases. The affected lymphoblasts in this subtype are large with regular nuclear 
shape 34.  
Recently, the World Health Organization (WHO) has classified the ALL subtypes into 
three different subgroups according to cytogenetic and immunophenotypic characterization 
as the following 35: 
1. Acute lymphoblastic leukaemia/lymphoma [mixture of FAB L1/L2]. This type 
includes:                                                                                                                          
a). Precursor B acute lymphoblastic leukaemia/lymphoma which are also in  turn 
classified into four cytogenetic subtypes: 
I. t(12;21)(p12,q22) TEL/AML-1  
II. t(1;19)(q23;p13) PBX/E2A  
III. t(9;22)(q34;q11) ABL/BCR  
IV. T(V,11)(V;q23) V/MLL  
        b). Precursor T acute lymphoblastic leukaemia/lymphoma. 
 2. Burkitt’s leukaemia/lymphoma  [FAB L3]. 
 3. Biphenotypic acute leukaemia 35.  
The FAB classification system is broadly used for clinical diagnostic and treatment, 
whereas the WHO system could be used for either scientific research or clinical purposes.   
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1.2.2.2 Chromosomal abnormalities  
 
In many developing leukaemic cells, there are detectable chromosomal alterations such as 
translocation, inversion, deletion or addition 30. Nowadays, chromosomal translocations are 
useful for identifying and diagnosing the subtype of acute lymphocytic leukaemia 30. 
Biologically, these translocations lead to activation of  certain transcription factors which 
in turn  control genes that control, either directly or indirectly,  cellular differentiation, 
proliferation or survival 30. About one fourth of recorded cases of acute lymphocytic 
leukaemia which occur during childhood are related to the TEL/AML-1 fusion protein, a 
consequence of translocation between chromosome 12 and 21, t(12;21)(p12,q22) 36,37. In 
mice, both Tel and AML-1 genes have a central role in haemopoietic-cell maturation 38. 
However, the TEL/AML-1 fusion protein is believed to be a pre-leukaemic cell inducer as 
it is responsible for the alterations of self-renewal processes as well as changes in survival 
and proliferation modes 39. In adults, more than 30% of ALL recorded cases are related to 
chromosomal translocation between chromosome 9 and 22  which is called the 
Philadelphia chromosome (figure1.2) 30,40. This translocation leads to fusion of the BCR 
protein to ABL, a non-receptor kinase, which in turn leads to downstream signaling events; 
the best known target pathway is the Ras-Mek-Erk signaling pathway which is considered 
to be involved in the regulation of genes that control cell survival, differentiation and 
proliferation 40.   
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Figure 1.2 Philadelphia chromosome. One of the common chromosomal translocations found in 95% of 
CML cases, 30% in adult and 5% in pediatric ALL patients. The translocation occurs between chromosome 9 
and chromosome 22, t(9;22) (q34;q11) ABL/BCR. This translocation produces ABL/BCR fusion protein  
which underlies the cell survival 29. 
 
 One of genetic lesions which induce many cases of B-cell progenitor acute lymphoblastic 
leukaemia is epigenetic silencing of cyclin-dependent kinase inhibitor 2A gene (CDKN2A) 
which encodes either the tumour suppressor p16 or p14 37. In the same context, several 
published analyses reveal a link between the alteration of the PAX5 gene and the onset of 
B-cell precursor lymphoblastic leukaemia 41. Furthermore, some genetic studies identified 
some kinds of chromosomal deletions in different cases of B-cell precursor acute 
lymphoblastic leukaemia such as IKZF3, IKZF1, LEF1,TCF3 (E2A) AND EBF1 (EBF) 42.  
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1.3 Integrins 
 
1.3.1 General Overview 
   
Integrins are membrane glycoproteins which play several vital roles in communication 
processes between intracellular and extracellular environments by mediating various 
intracellular signals. In addition, integrins play a major role in the regulation of cellular 
shape, mobility and the cell cycle 43. Moreover, integrins attach the cell to the tissue and 
are capable of revealing the status of the cell to the surrounding environment 44. This may 
reflect on the main function of whole organ or tissue, such as the role of GPIIb/IIIa in 
platelets and the coagulation process 44. 
In fact, integrins have been found in all mammals. There are many kinds of integrins and 
many cells have multiple types of integrin on their plasma membranes 44. So far, 18 α 
subunit genes have been identified and 8 β subunit genes 45. These subunits can form 24 
different kinds of integrin receptors that mediate a large spectrum of cellular functions and 
behaviours 45. 
1.3.2 General structure of integrins 
 
 In general, integrins are heterodimers composed of two distinct types of polypeptide 
chains, the α and β subunits 43. These subunits have numerous forms which cause the 
variety of integrins; for example, the αV subunit forms a heterodimer with β1, β3, β5, β6  
and β8 43. The α and β subunits have a short intracellular domain of about 40 – 70 amino 
acid residues, with the exception of the β4 subunit which has an intracellular domain of 
1088 amino acid residues 45. On the surface of cell, the extracellular domain of both the 
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α and β subunits lie close together and the N – terminal regions of each chain form a 
binding region for the extracellular matrix 46. The extracellular portion of α subunits 
contains about 1104 amino acid residues while the extracellular portion of β subunit is 
composed of about 778 amino acid residues 47. So far, we could say that the molecular 
weights of integrin subunits are different from one to the other but generally they are 
between 90 kDa – 160 kDa 48. The N-terminal regions of αVβ3 come together to form a 
globular head domain that generates the ligand binding site 47. This binding site head is 
linked to the membrane by a stalk which as a length of about 170Ǻ 47. Some mammalian 
α subunits have an extra 190 amino acid domain which is called the I domain (also 
known as vWFA domain) 49. Moreover, most β subunits can associate with more than 
one α subunit; for instance, β1 is found in association with 11 different α subunits 50. 
Therefore, there are several systems for classification and characterization of integrins, 
but the most of common one is αnβn where n  is the subunit number 51. The integrin 
subunits dimerization underlies the integrin binding  characteristics which in turn control 
the function of the integrin 50. For instance, α1β1 and α1β2 both bind to collagens or act 
as cell – cell adhesion molecules 50, 51; indeed, almost all of the β2 family are involved in 
cellular adhesion processes 50.   
Both α and β subunits contain several cations and the number of these cations depends 
on the presence of acidic amino acids in their structures 48. The role of the cations in the 
α subunits still unknown, but they may play a role in the stabilization of the folds of 
protein 46. However, the cations in the β subunits are involved in integrin – extracellular 
matrix interactions 47. In addition, β subunits have four cysteine – rich repeated 
sequences that may play a major role in that interaction 45.  
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1.3.3 General functions of integrins 
There are two major functions of integrins; attachment of the cell to the extracellular 
matrix and transduction of the signals between extracellular matrix and cytosol 52. 
Moreover, integrins are involved in many biological activities, including binding of 
viruses, cell migration, immune activation, etc 51,52. 
 
1.3.3.1 The role of the integrin family in cellular attachment   
 
The extracellular head domain of the heterodimer or in some cases the extracellular 
portion of the individual subunit, and particularly the α subunit, contains the ligand 
binding sites 53. The most well characterized target motif is an Arg-Gly-Asp (RGD) 
sequence which is present in many different adhesive ligands such as vitronectin and 
fibronectin 53. In general, integrins bind their ligand in the presence of divalent cations 
such as Ca2+,  Mn2+or Mg2+ 54. However, this cationic binding dependence varies 
between the integrin family members. For example, magnesium enhances the binding  of  
αVβ1 and α2β1 to their ligands but calcium does not, while the binding of αVβ3 to 
vitronectin can use either cation 55. Several functional  proteins which regulate cellular 
adhesion, migration or interaction bind to their target integrin either through the RGD 
motif or other motif such as the RKC motif in sCD23 55. This binding stimulates the 
intracellular domain of the integrin by causing conformational changes which may lead 
to cytoskeletal protein clustering or initiation of a certain signaling pathway in order to 
control cellular activity such as proliferation, survival or apoptosis 56. Many published 
studies reveal that several integrin family members contribute to many tumour 
malignancy behaviours such as proliferation, survival, metastasis, and invasion 57.       
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1.3.3.2  Integrin -  mediated signalling pathways 
 
The ability of integrins to perform their role as transmembrane bridges between the actin 
filaments of the cytoskeleton and the extracellular matrix is controlled by the Ras– 
related GTPase family 58. These communicating bridges are important not only for cell 
adhesion, but also for cell motility, migration and integrin–related signalling functions 
58
. 
Integrin – mediated signalling events can be divided into two groups; the first one is 
driven by ligands that bind directly to integrins causing them to cluster and directly 
activate signalling pathways  59. This pathway involves or activates cytoplasmic tyrosine 
kinases such as focal adhesion kinase (FAK) and serine/threonine kinases ( e.g., mitogen 
– activated protein kinase MAPK) 59.  
The second group of integrin – mediated pathways is called the "collaborative signalling 
pathway" which is initiated by other groups of receptors such as receptor tyrosine 
kinases (RTKs) which are activated by certain growth factors and which then  enhance  
integrin activation which leads to efficient transduction of signals 59. The affinity of 
integrin toward its ligands is controlled by intracellular inducers such as the active form 
of R-Ras which increases the binding affinity of ανβ3, α4β1 and α5β1 integrins for 
ligands 59.  
Integrins can also modulate MAPK phosphorylation through the classical MAPK 
signalling pathway of Ras/Raf/MEK/MAPK (ERK). This action depends upon either 
FAK, Src-family kinases (SFKs) or both together 60,61. Moreover, integrins activate 
several transcription factors as a downstream consequence of different signalling 
pathways. One of these transcription factors, NFκB, controls expression of a spectrum of 
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genes such as pro-inflammatory genes and some cytokines 62. Figure 1.4 summarizes 
some signalling pathways modulated by different integrin family members. 
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Figure 1.3 Signalling pathways modulated by different integrin family members. Integrins activate 
several transcription factors, in order to control different cellular activities or events such as proliferation, 
migration or differentiation. 
 
 
1.3.3.3 Growth factor signalling mediated by integrins  
 
 Integrins are able to modulate signalling pathways which are activated by soluble 
growth factors and other differentiation stimuli 58. This phenomenon has been observed 
in several cell lines and seems to be general. One of these pathways is the activation of 
RTKs which leads to the activation of mitogen signalling 58. According to Sundberg and 
Rubin, the integrin – mediated activation of platelet derived growth factor - β receptor 
(PDGFR-β) is independent of ligand ( i.e. PDGF )  63. In contrast, a highly tyrosine – 
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phosphorylated portion of PDGFR associates with ανβ3 integrin in the presence of 
vitronectin 64. So far, it is not clear whether the RTKs and integrins associate together 
directly or whether other cellular components are involved in their association 58. Some 
studies suggested that the efficiency of the MAPK cascade, which is enhanced by 
integrin – mediated adhesion, may involve Raf recruitment and activation 65. Other 
studies suggested that the activation of MAPK is enhanced by MEK rather than Raf 66. 
Recently it has been clear that integrin – dependent adhesion molecules play a major role 
in modulating growth signalling pathways via both RTKs and the MAPK cascade, 
meaning that integrin – dependent adhesion molecules have an importance in the 
regulation of the cell cycle and apoptosis 58. In addition, there are some reports showing 
that soluble growth factors, motility factors and differentiation factors require the 
activation of certain types of integrin 58. 
 
1.3.3.4 Integrin – mediated  apoptosis 
 
Apoptosis is an important biological process which regulates the growth of cells, 
whether normal or tumour cells, and the role of integrins in the apoptotic process has 
been recognised since 1996 67. Although the caspase family proteases have a major role 
in modulating apoptosis in both down and up stream events and in cooperation with the 
Bcl-2 family,  the activation of the Jun-kinase (JNK) cascade also has been shown to be 
an apoptotic mediator in some cell types 68. On the other hand, the activation of the PI3K 
– Akt cascade has been shown to be an apoptotic antagonist 69. Furthermore, some 
published work shows that FAK can be cleaved by caspase family proteases to initiate 
the apoptotic mechanism which, in turn, blocks the FAK – PI3K – Akt pathway 70. The 
role of integrin – mediated apoptosis is to maintain the expression of Bcl-2 which blocks 
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caspase activation 71. In addition, integrin – mediated signals can  activate the MEKK-1 
– JNK cascade which also leads to suppression of apoptosis 71. In conclusion, integrin – 
mediated signalling pathways play a regulatory role in a network of cellular events such 
as adhesion, apoptosis, growth, proliferation, differentiation and mobility.  
 
1.3.4  αν integrin structure and its importance 
According to Nemeth (2007), the structure of αν integrin is different from the other types 
of integrins, because the α subunit can bind one of five different β subunits, β1, β3, β5, 
β6 and β8 subunit 72. αv integrins play a major role in wound healing due to their ability 
to bind to vitronectin and fibronectin as well as their role as collagen receptors 73. αvβ3 
is a member of αν integrin subfamily and has an important role in tumour growth, 
tumour – linked angiogenesis and metastatic processes 74. There is some evidence that 
has shown high levels of  ανβ3  integrin on many sold tumours, such as cancers of 
kidney, breast, lung, prostate, ovary and skin 75,76. Moreover, ανβ3  integrin plays a key 
role as a mediator in spreading and migratory properties of human melanocytes 77. Both 
ανβ3 and ανβ5 are highly expressed on osteosarcoma cells and both of them can mediate 
adenovirus infection 78 . 
Unfortunately, any functional or structural alteration in integrins may promote many 
health problems such as cancer, tumour growth, metastasis, coagulation, bleeding, etc 74, 
79
. Hence, the recent research interest in anti-cancer therapies directed toward αν integrin 
72
. In a different context, αν integrins regulate the blood vessels formation during the 
embryonic progression 80. Bader and his group have investigated the role of αν integrins 
in vascularisation by using αν integrin knockout mice. They found about  80% of these 
mice die in utero while 20% die a few hours after  birth and this was a accompanied by 
 39 
extensive abnormalities in brain vessels, intestinal vessels and bleeding 80. These 
findings suggested that αν integrins are important in either blood vessel formation or 
maturation. A supportive study was conducted by Yang and his group where they found  
hemorrhagic disorders in β3 knockout mice 81. 
 
1.3.5  Integrins and leukaemia 
 
Integrins play an essential role in cellular adhesion which in turn plays an  important 
anti-apoptotic role in both normal and leukaemic B-cells 82. Apoptosis was induced  
using monoclonal antibodies against either VCAM-1 or α4β1 integrin 83. These findings 
explained the role of integrin in the cellular adhesion between leukaemic and stromal 
cells which is believed to be essential for precursor B  leukaemic cell survival 83. In pre-
B acute lymphoblastic leukaemia, integrins modulate different signaling pathways which 
may underlie cell survival 84. In the same context, integrins upregulate both Bcl-2 and 
Bcl-xL genes 84. Bcl-2 and Bcl-xL are proteins that contribute to the anti apoptotic 
process. In addition, Matsunaga and his group have found that the interaction between 
fibronectin and VLA-4 leads to Bcl-2 upregulation as an outcome of the activation of the 
PI3K/Akt cascade in acute myelogenous leukaemia (AML) cell lines 85. Furthermore, 
the stimulation of  β1 integrin in pre-B acute lymphocytic leukaemia (ALL) inhibits both 
caspase-3 and caspase-7 as well as inducing the expression of two apoptosis inhibitor 
proteins which are called Survivin and X-linked inhibitor of apoptosis protein (XIAP) 86.  
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1.4  CD23 
 
1.4.1 CD23 structure 
 
CD23, also known as (FcεRII), is a glycoprotein with a molecular weight of 45 KDa and 
is usually present on many immune cell membranes, especially B – lymphocytes and 
monocytes 87. In fact, it is expressed in many different cell types such as Langerhans 
cells, endothelial cells, platelets, follicular dendritic cells and some epithelial cells 88 In 
addition, this protein is sometimes present free in blood and called soluble CD23 
(sCD23) 87. 
Although CD23 is considered an Fc receptor, its structure is different from other Fc 
receptors 89. Membrane bound, trimeric CD23 is composed of three portions; head, stalk 
and tail. The head portion is the C - terminal extracellular portion and is composed of 
three C – type lectin domains 90, 91. The stalk also is an extracellular portion which is 
composed of a trimeric α helical coiled – coil containing N – linked glycosylation sites; 
the cytoplasmic tail is the N- terminal intracellular portion 89, 91. The extracellular 
portions are composed of 277 residues while the transmembraneous domain and the 
cytoplasmic terminal are composed of  20 and 23 residues, respectively 92.   
CD23 can bind to both CD21 and IgE simultaneously through specific binding sites in 
the extracellular lectin domain 93. Two lectin domains can bind to Cε3 domains in IgE. 
However, the third lectin domain of CD23 expresses one to three binding sites for CD21 
94
.The interaction between CD23 and IgE is Ca2+ dependent. However, the interaction 
between CD23 and CD21 is carbohydrate-dependent 88. Figure 1.4 shows the binding 
sites on CD23 lectin domains, the binding site shown in yellow colour is specific for 
binding the αVβ5 integrin which was identified by our laboratory 95. 
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Figure 1.4 Binding surfaces on human CD23.  The lectin domains of human CD23 have three 
distinct binding sites IgE binding sites (blue), CD21 binding site (red) and αV integrin binding  
site (yellow). This figure is adapted from Borland et al 95  
 
 
There are two different forms of CD23. These forms are different in their structure     
and location. The first form, called CD23a, is different in the N – terminal six amino 
acids from the other form, CD23b 88. CD23a is usually present on B- cells while CD23b 
is present on a variety of cell types 88. Furthermore interleukin – 4 is required for  
CD23b expression on B cells  88. 
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Figure 1.5 CD23 structure. It is composed of three parts, C-terminal portion which contains the 
binding sites, the coiled-coil stalk containing the glycosylation site and the N- terminal portion 
which is the cytosolic portion. This figure is adapted from  ( Sutton and Gould, 1993 ) 91. 
 
CD23 normally undergoes proteolytic processing via metalloprotease enzymes that 
release soluble CD23 into serum 96. There are many products of proteolytic cleavage of 
CD23 and these products differ in sizes and functions 96. This cleavage process occurs in 
the coiled-coil stalk as it is susceptible to proteolysis 97. CD23 cleavage produces 37, 33, 
29, 25 and 16 KDa fragments all of which contain the C-terminal domain 96. Some 
papers reported that the fragments which have molecular weight more than 25000 MW 
promote IgE synthesis 96,98. On the other hand, the fragments of cleaved CD23 which 
have molecular weight equal or less than 25000 MW suppresses IgE synthesis 98.       
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1.4.2 CD23 function 
 
 CD23 binds different ligands such as immunoglobulins (IgE), glycoproteins (CD21) and 
viruses such as Epstein Barr Virus (EBV) 99. CD23 plays many important roles in 
regulation of IgE production, control of histamine production and T – cell / B – cell 
interactions 100. CD23 is capable of linking IgE with another glycoprotein CD21 and this 
binding is a trigger for IgE production and, according to that model, CD23 plays a major 
role in IgE production as a positive regulator 101. The CD23/CD21 – IgE complex also 
requires other stimulation effectors such as interleukin – 4 and interleukin – 13 99, 102. 
The inducing role of these effectors is sometimes blocked by interferon γ, interferon α 
and prostaglandin E2. 102,103.   
Moreover, the production of IgE requires T – cell / B – cell interaction, a process 
enhanced by CD23; this has been proved in vitro by using anti-CD23 monoclonal 
antibodies, where the results clarified that there was no interaction between T and B – 
cells in the presence of the CD23 antibody 104. The other possible role of CD23 is 
regulating histamine production due to its binding to CD21 on the surface membrane of 
basophils 105. Furthermore, a high concentration of free CD23 fragments in plasma is 
usually associated with inflammation and some diseases such as asthma, chronic 
lymphoblastic leukaemia and rheumatoid arthritis 106. Clinically, an increased serum 
CD23 level was found in systemic lupus erythematosus, primary Sjogren's syndrome, 
glomerulonpharitis and  rheumatoid synovitis  107,108,109. 
In addition, soluble CD23 stimulates monocytes to produce both tumour necrosis factor 
– α (TNF-α) and interleukin – 1α 110. Consequently, sCD23 interacts with interleukin – 
1α to stimulate the differentiation of monocytes 110. In this context, soluble CD23 
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interacts with CD11b (αMβ2) and CD11c (αXβ2) on monocytes,  which drives 
monocytes to produce proinflammatory mediators such as interleukin-1α, interleukin-1β, 
interferon- γ and interleukin-6 94. The CD23-CD11b/CD11c interaction also increases 
levels of nitrate, hydrogen peroxide and other oxidative products 94. 
In human B lymphocytes, soluble CD23 interacts with IgE which leads to increased Ca2+ 
and cyclic-AMP levels 111. Moreover, membranous CD23 acts as signal transducer when 
cross-linked with several B cell membrane proteins such as MHC class II , CD9,CD81 
and CD82 112,113. Recently, some researchers reported that CD23 plays an important role 
in supporting the survival of pre B – cells via its binding to ανβ5 integrin 95. 
 
 
1.4.3 CD23 – ανβ5 integrin interaction 
 
The ανβ5 integrin, like other integrins, is a heterodimeric transmembraneous receptor 
composed of two protein subunits, αV and β5 43. The ανβ5 integrin is one of the 
vitronectin receptors which means that the ανβ5 integrin plays several roles in cell 
attachment, survival and growth 114,115,116. In addition, in tumours, the ανβ5 integrin is 
implicated to be one of the important mediators of tumour growth, metastasis and 
angiogenesis 95,117. 
The ανβ5 integrin interacts with its ligands such as vitronectin and fibronectin via a 
distinct binding motif, known as the RGD motif, which is arg-gly-asp 53,118,119. In a 
different context, soluble CD23 also interacts with different integrin family members 
and this interaction underlies the production of different cytokines such as IL-1α, IL-1β, 
IL-6 and IFN-γ  as well as proinflammatory mediators such as interleukin-1β, 
interleukin-6 and tumour necrosis factor-α 106,120,121,122. 
 45 
 Recently, our laboratory has found that the ανβ5 integrin recognizes an arg-lys-cys 
(RKC) motif on sCD23 in an adhesion – independent interaction 95. In addition, this 
interaction plays an important role in the growth of pre – B cells, and also activates ERK 
123
. Furthermore, ERK activation was increased in the presence of SDF1 123. These 
findings suggest that the activation of ERK might underlie B-cell survival and growth, 
and that any enhancement or synergistic effect from the bone marrow microenvironment 
such as stromal cell – derived factor 1 (SDF1) and/or platelet derived growth factor 
(PDGF) might be delivered via ERK.   
1.4.4  Other ligands related to haematopoiesis and ανβ5 
integrin 
 
1.4.4.1 Stromal cell – derived factor 1 (SDF1) 
      
Stromal cell – derived factor 1 (SDF1 or CXCL12) is a chemokine which plays several 
roles during B – cell development in bone marrow 124. SDF1 is produced by immature 
osteoblasts in bone marrow and by epithelial cells in different organs 125,126,127. SDF1 is 
composed of 67 residues, is about 8KDa, and presents in all vertebrates in different 
isoforms SDF1α, SDF1β, SDF1γ, SDF1ε and SDF1φ 128,129,130. Both SDF1α and SDF1β 
encoding genes are located on chromosome 10 131. Recently, several studies have 
demonstrated the ability of SDF1 to activate some types of integrins such as LFA-1, 
VLA-4 and VLA5 and to play a synergistic role with cytokines which might be required 
for cell survival and proliferation 132,133,134. SDF1 certainly plays an essential  role in 
haematopoietic cell maturation, survival and proliferation 135. In addition, in various cell 
types including B cell precursors, SDF1 increases the intracellular calcium levels via 
ligation of CXCR4 136,137. This ligation also leads to the activation of 
 46 
phosphatidylinositol 3 – kinases (PI3K) and phosphorylation of MEK and ERK as a 
consequence of phosphorylation of focal adhesion complexes 138. Moreover, SDF1 
stimulates the Jak/STAT pathway 139. On the other hand, SDF1 is thought to play 
different pathological roles such as HIV infection enhancement, tumour growth, 
inflammation and angiogenesis 140,141,142. In terms of leukaemias, CXCR4 is highly 
expressed in B- chronic lymphocytic leukaemia cells which enhances their response to 
SDF1 143. Meanwhile, the migration, cellular adhesion and survival of  different acute 
lymphocytic leukaemia cell lines are enhanced in the presence of  SDF1144,145.       
 
 
1.4.4.2  Platelet – derived  growth factor (PDGF) 
 
Platelet – derived  growth factor (PDGF) was recognized and detected in whole blood 
cells but was absent in the plasma 146. The major source of Platelet derived growth factor 
(PDGF) is the α – granules of platelets and it is synthesized by other cell types such as 
macrophages, epithelial and endothelial cells 147,148,149. Several studies show that PDGF 
plays a significant role in several physiological systems such as cellular development 
and growth. On the other hand, PDGF is implicated in several pathological mechanisms 
including atherosclerosis, fibrosis and neoplasia 150,151,152. 
PDGF is composed of two polypeptide chains linked together by a disulphide bond 153. 
There are four distinct polypeptide chains A, B, C and D, which are assembled to form 
the dimer of PDGF, whether homodimers such as PDGF – AA, PDGF – BB, PDGF – 
CC and PDGF – DD or heterodimers such as PDGF – AB 154,155,156. 
PDGF binds to its target cells via two types of receptors PDGFR – α and PDGFR – β, 
and both are similar to each other in their structures 157. The PDGFR – α has a high 
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affinity toward A, B and C chains, while the PDGFR – β recognizes and binds to the B 
and D chains 158. However, PDGF requires proteolytic cleavage before being able to 
bind to the PDGFR 159. The PDGF exerts its biological role by inducing the dimerization 
of receptors which leads to autophosphorylation of the PDGF receptor tyrosine kinase 
(RTK) 160. In turn, the RTK phosphorylates many downstream signalling proteins 160. 
 According to Soliven and his colleagues, PDGF stimulates both  Src family kinases and 
sphingosine kinase in oligodendroglial progenitors 161. Recently, some studies have 
shown that the PDGF induces cellular proliferation, migration and differentiation via the 
RAS/MAPK pathway and promotes cell survival through PI3K/Akt pathway 162,163,164. 
Furthermore, PDGFR directly mediates STAT1 activation and phosphorylates STAT3 
via the phosphorylation of  JAK protein in fibroblasts 165,166. In addition, Paukku and his 
colleagues have published that PDGF induces the activation of both STAT5 and c-Src in 
mammalian cells 167. PDGF induces cell growth via STAT5 phosphorylation   in 
different types of leukaemia such as AML and CML  168,169,170. Figure 1.6 summarizes 
some of signalling pathways mediated by the PDGF; Ras/Raf/MEK/ERK pathway, 
JAK/STAT pathway and PI3K/Akt pathway. 
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Figure 1.6 PDGF signalling. PDGF induces several signalling pathways depending on the cell 
type and condition. 
 
1.4.4.3  Vitronectin  
 
Vitronectin is a 75 kDa glycoprotein present in the extracellular matrix and plasma 171, 
172
. Vitronectin has different binding sites so that it is a multifunctional protein 171. One 
of these binding sites is the Arg-Gly-Asp (RGD) motif  which is located in the N-
terminal domain and is involved in the cellular attachment via the vitronectin-integrin 
crosslink 173. In humans, the vitronectin gene is located in the long arm of chromosome 
17 174.  
Vitronectin plays several biological roles such as cellular adhesion, spreading and 
migration 173,175. In addition, vitronectin is involved in physiological processes such as  
haemostasis via its binding to heparin, the immune response by its binding to the 
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terminal complex in the complement protein cascade and in cell proliferation as a co-
stimulant growth factor 171,173,175. 
Pathologically, vitronectin is implicated in several disease processes such as 
arteriosclerosis, degenerative central nervous system disorders, fibrosis and membranous 
nephropathy 176. Vitronectin is involved in angiogenesis and tumour growth due to its 
interaction with ανβ3 integrin 177. Moreover, vitronectin plays an important function in 
wound healing via its binding to some of integrin family members 178.    
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1.5 Signalling pathways related to cell growth, survival 
and proliferation 
 
1.5.1 JAK/STAT signalling pathway 
 
Janus Kinases are intracellular proteins identified as tyrosine kinases involved in cell 
survival and growth stimulated by different growth factors, cytokines and interferons 179, 
180
. At present, there are four members of the JAK family in mammals,  JAK1, JAK2, 
JAK3 and Tyk2 181. The molecular weights of these kinases are between 120 and 140 
KDa  and they have similar structure 181. Each JAK family member is composed of 
seven highly conserved domains called JAK homology domains (JH) 182,183. The kinase 
activity domain is in the C-terminal domain, which is called the JH1 domain, and this 
domain is followed by JH2, a kinase-related domain 184. The structural differences 
between JAKs are located in the remaining five domains in which the degree of 
conservation varies from one to the other 182. JAKs are activated by transmembraneous 
cytokine and growth factor receptors. Normally, these receptors are associated with one 
member of the JAK family via the intracellular domain 185,186,187. These receptors 
undergo ligand-driven conformational changes leading to either multimerization, such as 
with cytokine and interferon receptors, or dimerization, as noted in PDGF and growth 
factor receptors 188,189. This action leads to JAK phosphorylation and phosphorylated 
JAKs in turn either phosphorylate the receptor itself or other downstream substrates 187. 
 The major JAKs substrates are called signal transducers and activators of transcription 
(STATs) 190. The STAT family is composed of seven members STAT1, STAT2, 
STAT3, STAT4, STAT5a, STAT5b and STAT6 190. In humans, STAT1 and STAT4 
genes are located on chromosome 2 whereas STAT2 and STAT6 genes are located on 
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chromosome 12 191,192. The other STAT family members STAT3, STAT5a and STAT5b 
genes are located on chromosome 17 191,192. Structurally, STATs are different from other 
transcription factors because they have Src-homology 2 (SH2) domains 191,193. These 
domains are responsible for STAT dimerization and activation  191. Once STAT becomes 
phosphorylated at the SH2 domain the dimerization will start between SH2 domain of 
one monomer and the C-terminal of phosphotyrosine-binding domain of the other 194,195. 
The activation of STATs produces either heterodimers such as STAT1-STAT2 and 
STAT1-STAT3 or homodimers such as STAT1 and STAT3  193,194. 
In general, the JAK/STAT pathway plays several different roles in mammals and other 
vertebrates corresponding to the stimuli, cell type and biological context. Many 
published studies have revealed that the JAK/STAT pathway mediates several cellular 
and  biological functions such as proliferation, apoptosis and growth in response to 
either cytokines, interferons or growth factors. 
 In haematopoietic cells, the JAK/STAT pathway was identified in different cases either 
in normal or malignant cell lines. In 1997 Lacronique and his colleagues identified TEL-
Jak2 fusions  in  early B-precursor acute lymphoblastic leukaemia as a product of  
t(9;12)(p24;p13) translocations 196. Similar data were shown in chronic myeloid 
leukaemia but with additional translocations t(9;15;12)(p24;p15;p13) 197. In both cases, 
the transcription factor Tel is fused to the JH1 domain of Jak2 and consequently 
activates STAT1 and STAT5 198,199, 200. In addition, both STAT3 and STAT5 were found 
activated in response to different cytokines and growth factors in several leukaemic cell 
line models 200,201,202, 203. Moreover, the anti-apoptotic role of STAT3 has been shown in 
multiple myeloma in which the activated STAT3 in turn promotes Bcl-2 and Bcl-xL 
expression 204. Several published papers have reported that gamma interferon-activated 
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site (GAS) is the main site that activated STATs bind in order to regulate their target 
genes in response to different stimuli such as cytokines, hormones and growth factors 
205,206,
 
207
. Figure 1.7 describes the general activation steps of JAK/STAT pathway that 
occur in different cell types in mammals. 
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Figure 1.7 JAK/STAT pathway. Dimerization and auto-phosphorylation of Tyrosine kinase 
receptors can be caused by different ligands such as interleukins and growth factors. (1) 
Receptor tyrosine kinase and Jak phosphorylation by ligand-driven conformational changes. (2)     
Phosphorylated receptor kinase recruits and phosphorylates STATs. (3) Phosphorylated STAT 
forms active dimers. (4) Activated STAT translocates into the nucleus. (5 The activated STAT in 
turn binds DNA at specific binding sequence mainly (GAS) and activates the transcription of 
target genes.    
 
  
1.5.1.1 STAT5 structure and function 
 
STAT5 is a name of two highly conserved STAT family monomers STAT5a and 
STAT5b. STAT5 was identified in 1994 by Groner and his group in mammary 
epithelium and was called at that time Mammary Gland Factor (MGF) 208. STAT5a is 
composed of 793 amino acids whereas STAT5b contains 786 amino acids. The 
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similarity between the proteins reaches up to 96% and the variability between them is 
located in the C-terminal transactivation domain 209, 210,211.  
The structure of either STAT5a or STAT5b is similar to other STAT protein; composed  
of  N-terminal domain followed in order by coiled coil, DNA binding domain, linker 
region, SH2 and transactivation domains which is in the C-terminus 211,212. The linker 
region is responsible for dimerisation which is essential for the transcriptional activity of 
STAT5. The dimerisation produces either homodimer (STATa/a) or heterodimer 
(STAT5a/b), however, it requires the phosphorylation of either of them at a specific 
target residue, at Tyrosine 694 for STAT5a and Tyrosine 699 for STAT5b 208, 213. The 
phosphorylation event in either isoform typically occurs by the receptor associated 
tyrosine kinase proteins Jaks, Jak1, Jak2 or Jak3 214. The phosphorylation of Jak occurs 
via receptor tyrosine kinase and then the activated Jak in turn cross-phosphorylates the 
receptor tyrosine kinase which recruits either STAT5a or STAT5b and binds to any of 
them via SH2 domains and phosphorylates a specific tyrosine residue which induces 
STAT5 dimerisation 215, 214, 216. STAT5 dimers translocate into the nucleus in order to 
regulate the target genes 214. 
STAT5 regulates a wide range of genes depending on the cell type, the stimuli and the 
cell condition. The most well known gene is Bcl-XL the gene that encodes Bcl-XL 
protein that acts as an anti-apoptotic protein 217, 218, 219,220. Many published reports have 
revealed that STAT5 regulates various genes in different species and cell types. Some 
studies show that  STAT5 regulates cytokine genes and cyclin D 221, 222,223. 
In general, STAT5 plays different biological and pathological roles such as preventing 
cell death, cell cycle stimulation, cytokine secretion and tumour growth 223, 224, 221, 225.  
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In normal conditions, IL-7 plays an essential role in early B-cell development via 
activating STAT5, and STAT5a/b is also required for survival of CD8+ T cells 226, 227. In 
addition, STAT5 controls Bcl-6 expression in germinal centre B cells which leads to 
self-renewal and differentiation of  human memory B cells 228. Furthermore, STAT5 
activation was found associated with different leukaemias due to its role in apoptotic 
prevention or cell cycle regulation  219, 229, 230.   
 
1.5.2 The ERK1/2 mitogen-activated protein kinase pathway 
 
ERK1 and ERK2 are intracellular proteins expressed in almost all cell types with 
molecular weights 43 and 41 KDa, respectively 231. Both ERK1 and ERK2 proteins have 
85% an identical core where the substrate binding sites are located 231, 232. Furthermore, 
the activation site which contains the phosphate acceptor residues tyrosine and threonine  
is located in a TEY motif in the activation loop in both ERK1 and ERK2 232, 233. The two 
proteins are activated by different stimuli such as serum, cytokines, growth factors and 
several G protein-coupled receptor ligands 232, 233. 
The activation of ERK1/2 was found linked with several biological actions such as cell 
growth, survival and proliferation in different cell types. Moreover, there is some 
evidence that the activation of ERK is required for  cell cycle progression, precisely for 
cell transition from G1 phase into S phase which means that the activated ERK is also 
required for DNA synthesis 234, 235, 236. 
The Ras/Raf/MEK/ERK signaling pathway is the main upstream signaling cascade for 
ERK and ERK seems to be the key target of this pathway. However, ERK is involved in 
different downstream signaling pathways illustrated in figure 1.6. ERK is identified as a 
kinase of either c-Fos or c-Myc in order to induce cyclin D1 gene expression which in 
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turn controls the cell cycle 237,238. Phosphorylated ERK is also responsible for Elk-1 
phosphorylation at multiple Ser/Thr-pro sites 239. The activated Elk-1 interacts with the 
serum response factor (SRF) to form the ternary complex factor (TCF) which in turn 
regulates serum response element (SRE) transcriptional activity 240, 241, 242. According to 
Marais and his group, the activation of  the SRF-DNA interaction is ERK2 dependent 
242
. In other contexts, ERK is identified as a kinase of p90RSK, MSK and c-Jun 243, 244, 
245
. 
F
igure 1.8 The Ras/Raf/MEK/ERK cascade. ERK1/2 plays a key role in several cellular 
activities. The activation of ERK1/2 via the Ras/Raf/MEK regulates expression of many genes  
via  activating different transcription.   
 
The MAP Kinase pathway is implicated in several physiological disorders such as 
tumour growth, metastasis and angiogenesis  246, 247, 248. In addition, the superoxide 
activated-Ras/Raf/MEK/ERK pathway is implicated in renal dysfunction, dementia and 
Parkinson’s disease 249, 250, 251.  
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In haematopoiesis, the Ras/Raf/MEK/ERK cascade plays different roles depending on 
the cell type and the maturation step it is involved in. The activation of MEK/ERK 
signaling by stem cell factor (SCF) stimulates the haematopoietic stem cell proliferation 
252
. Furthermore, the activation of MEK/ERK pathway as a downstream effecter of 
cytokine receptors is involved in different  maturation steps in either lymphoid or 
myeloid lineages 253, 254. On the other hand,  activated ERK was found in about 75% of 
AML cases in a study conducted by  Ricciardi and his colleagues 255. In addition, 
ERK1/2 seems to be a significant indicator for both B-ALL  and T-ALL patients 256, 257. 
In the same context, the MEK inhibitor U0126 reduces growth of either AML or CML 
cell lines 258, 259. 
 
1.5.3 Calpain 
 
 
Calpain is a biochemical system composed of three components; two calcium-
dependent proteases, called µ-calpain and m-calpain, and the third component is a 
peptide called calpastatin which serves as an inhibitor for both µ and m Calpains 260. 
These three proteins are present in almost all cell types in all vertebrates but in 
variable  ratios depending on the cell type, tissue and species 260. Both Calpains µ and 
m are cytoplasmic cysteine proteases playing several biological roles in cell mobility 
and embryonic development due to cleaving the cytoskeletal proteins 261 , 262. In 
addition, both µ and m Calpains play different roles in cell signaling and apoptosis via 
cleaving caspase-7, -8, -9 and caspase-3 or via activating caspase activators such as 
APAF-1 and cytochrome C 263, 264. 
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1.6 Research aims 
 
The major aim of this study is to  investigate the role of the sCD23- αVβ5 integrin  
interaction in survival of acute lymphocytic leukaemia cells and to answer the question 
how the interaction leads to regulation of growth.   
The specific aims of this project are to: 
 
(a) Study the role of both  sCD23 and vitronectin in B-cell progenitor growth. 
(b) Study the synergy of PDGF(AB) and SDF1-α with sCD23 in B-cell precursors 
growth. 
(c) Study the activation of kinases in signaling pathways due to the effects of CD23 
and vitronectin. 
(d) Investigate the role PDGF receptor in the signaling events caused by sCD23- 
αVβ5 integrin interaction. 
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2. Materials and methods 
2.1 Chemicals and reagents 
All routine chemicals and reagents unless otherwise listed in Table 2.1 and Table 2.2 
were purchased from Sigma -Aldrich Company Ltd, Poole, UK and Fisher Scientific UK 
Ltd, Leicestershire, UK. 
          Table 2.1 Chemicals and reagents used in this study 
Chemical / reagent Supplier 
MES SDS Running Buffer 
(NuPAGE®) 
MOPS SDS Running Buffer 
(NuPAGE®) 
NuPAGE 10% Bis-Tris Gel 1.0mm 
NuPAGE 4-12% Bis-Tris Gel 1.0mm 
Invitrogen, Paisley, UK  
3MM chromatography paper 
3MM blotting paper  
PROTRAN nitrocellulose transfer 
membrane 
Whatman, Springfield Mill, 
Maidstone, UK 
Nucleic acid transfer membrane 
Hybond-N+ 
Amersham Life Science Ltd. 
Buckinghamshire, UK. 
Prestained Protein Marker, Broad 
Range (7-175 kDa) 
New England BioLabs, Hitchin, 
Hertfordshire, UK 
[Methyl-3H] Thymidine   GE Healthcare. Pollards Wood 
Nightingales Lane, UK 
X-tremeGENE 9 DNA Transfection 
reagent 
X-tremeGENE HP DNA Transfection 
reagent 
Roche Diagnostics  Limited, Charles 
Avenue, Burgess Hill, West Sussex 
UK 
Mirus TransIT-TKO Transfection 
reagent 
Cambridge Bioscience Ltd, Munro 
House, Cambridge, UK  
 
FuGENE HD Transfection reagent Promega UK Ltd, Southampton, 
United Kingdom. 
           
           
          Table 2.2 Kits were used in this study 
KIT SUPPLIER 
Nuclear Extract  KIT ACTIVE MOTIF Rixensart, Belgium Catalog No: 40010 
Proteome Profiler Antibody Arrays R&D   SYSTEMS,  Abingdon, UK 
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KIT SUPPLIER 
STAT5b EMSA KIT 
Panomics Catalog No; AY1405 via 
Caltag-Medsystems Limited, Whiteleaf 
Business Centre, 11 Little Balmer, 
Buckingham, MK18 1TF 
Catch and Release 
Immunoprecipitation KIT 
Millipore (U.K.) Limited, Building 6 
Croxley Green Business Park, Watford 
 
Calpain Activity Assay KIT Abcam, Cambridge Science Park, Cambridge, UK 
Luciferase Assay System 
ONE-Glo™ Luciferase Assay 
System 
Promega UK Ltd, Southampton, United 
Kingdom. 
 
 
2.2 Ligands, inhibitors and Antibodies 
 
All ligands and inhibitors used in this study were purchased from different suppliers are 
listed in Table 2.3. Table 2.4 summarized the information about the antibodies which are 
used in this study and the supplier of each. 
Table 2.3  Peptides and inhibitors were used in this study 
Peptides/inhibitors supplier 
Recombinant Human CD23/Fc 
epsilon  RII. 
Recombinant Mouse CD23/Fc 
epsilon  RII. 
Recombinant Mouse IL-3 
R&D SYSTEMS, Abingdon, UK 
Vitronectin 
PDGF-AB Sigma -Aldrich Company Ltd, Poole, UK 
SDF-1α 
Millipore (U.K.) Limited, Building 6 Croxley 
Green Business Park, Watford 
 
Long peptide (derived fromCD23) Mimitopes, Victoria, Australia 
Tryphostin AG490 (Jak2 
inhibitor) 
Tryphostin AG 1295 (PDGFRβ 
inhibitor) 
ENZO Life Sciences Ltd, Matford Court, UL 
MEK inhibitor (U0126) Promega Ltd, Southampton, Hampshire, UK 
PI3kinase inhibitor (LY 294002) New England BioLabs, Hitchin, Hertfordshire, UK 
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Table 2.4  Antibodies were used in this study 
Antigen Source Clone/Cat. No. Isotype Supplier Conjugate 
Human β3 
integrin 
Mouse 
monoclonal MHF4 IgG1 
Santa Cruz 
Biotechnology, 
Inc. Heidelberg, 
Germany 
FITC 
Human CD45 Mouse 
monoclonal BRA- 55 IgG1 
Sigma -Aldrich 
Company Ltd, 
Poole, UK 
FITC 
Human CD5 Mouse 
monoclonal UCTH2 IgG1 FITC 
Human CD10 Mouse 
monoclonal HI10a IgG1 PE 
Human CD19 Mouse 
monoclonal TB28-2 IgG1 FITC 
Human IgM Mouse 
monoclonal G20-127 IgG1 FITC 
Human CD34 Mouse 
monoclonal 563 IgG1 
BD Bioscience, 
Oxford, UK 
PE 
Human αVβ5 
integrin 
Mouse 
monoclonal P5H9 IgG1 PE 
Human CXCR4 Mouse 
monoclonal 12G5 IgG1 FITC 
Human CD23 Mouse 
monoclonal 138628 IgG1 PE 
Human PDGFRβ Mouse 
monoclonal PR7212 IgG1 FITC 
Human Phospho-
ERK1/2 
(T202/Y204) 
Rabbit 
polyclonal FTE12 IgG _ 
Phospho-STAT5 
(Y699) 
Rabbit 
polyclonal ZBS02 IgG _ 
Rabbit IgG Goat polyclonal FIN03 IgG 
R&D 
SYSTEMS, 
Abingdon, UK 
HRP 
Human IgG Goat polyclonal A0170 IgG HRP 
Rabbit IgG Goat polyclonal A6667 IgG HRP 
Mouse IgG Goat polyclonal A4416 IgG 
Sigma -Aldrich 
Company Ltd, 
Poole, UK 
HRP 
Rabbit IgG Goat polyclonal 7074 IgG 
New England 
BioLabs, 
Hitchin, 
Hertfordshire, 
UK 
HRP 
Non-human 
antigens 
Mouse 
monoclonal GO1 IgG1 FITC 
Non-human 
antigens 
Mouse 
monoclonal GO1 IgG1 
DAKO, 
Cambridgeshire, 
UK PE 
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Table 2.4  Antibodies were used in this study 
 
Antigen Source Clone/Cat. No Isotype Supplier Conjugate 
Human STAT5 Rabbit polyclonal 9363 IgG _ 
Human PDGFRβ Rabbit 
monoclonal 28E1 IgG _ 
Human Phospho-
p90RSK(S308) 
Rabbit 
monoclonal 9D9 IgG _ 
Human Phospho-
p90RSK 
(T359/S363) 
Rabbit 
polyclonal 9344 IgG _ 
Human Phospho-
p90RSK(T573) 
Rabbit 
polyclonal 9346 IgG _ 
Human 
RSK1/RSK2/RSK3 
Rabbit 
monoclonal 32D7 IgG _ 
Human Phospo-
p44/42 MAP 
Kinase 
Rabbit  
monoclonal 197G2 IgG _ 
Human Akt Rabbit polyclonal 9272 IgG _ 
Human Phospho-
Akt (S473) 
Rabbit 
monoclonal 193H12 IgG _ 
Human p44/42 
ERK1/2 
Rabbit 
monoclonal 137F512 IgG _ 
Human NF-kappa 
B2 p100/p52 
Rabbit 
polyclonal 4882 IgG _ 
Human Phospho-
JAK2 
(Y1007/1008) 
Rabbit 
monoclonal C80C3 IgG _ 
Human CREB Rabbit 
monoclonal 48H2 IgG _ 
Human Phospho-
CREB (S133) 
Rabbit 
monoclonal 87G3 IgG 
New England 
BioLabs, 
Hitchin, 
Hertfordshire, 
UK 
_ 
Human JAK2 Rabbit polyclonal NG1548937 IgG _ 
Human Phspho-
JAK2 
(Y1007/1008) 
Rabbit 
polyclonal 30220 IgG _ 
Human β5 integrin Rabbit polyclonal AB1926 
Whole 
serum 
_ 
Human Phospho-
STAT5a/b 
(Y694/699) 
Mouse 
monoclonal 8-5-2 IgG 
Millipore 
(U.K.) 
Limited, 
Building 6 
Croxley 
Green 
Business 
Park, 
Watford 
 
_ 
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2.3 Buffers 
 
The following table is listed the buffers which were routinely used: 
 
          Table 2.5  Buffers were used in this study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4 Plasmids and Oligonucleotides  
 
Plasmids were used as a reporter vectors in this study and oligonucleotides are listed 
in the following table. 
      Table 2.6  Plasmids and oligonucleotides were used in this study 
Plasmid/Oligonucleotide Supplier 
pGL4.34[luc2P/SRF-RE/Hygro] 
Vector 
Promega UK Ltd, Southampton, United 
Kingdom. 
TransLucent GAL4-STAT5B TAD 
fusion protein expression vector, 
pTL-STAT5B. 
Panomics Inc. And  Caltag MedSystems 
Ltd, Cambridge, UK  
Buffer Composition 
PBS 130mM NaCl, 27mM KCl, 4.3mM 
Na2HPO4, 1.4mM KH 2 PO 4  (pH 7.2) 
TBS 50mM Tris HCl (pH 7.4), 150mM NaCl 
TBS/T 50mM Tris HCl (pH 7.4), 150mM NaCl 
+ 0.1% (v/v) Tween20 
Stripping buffer 200mM Glycine, 0.1% (w/v) SDS, 1% 
(v/v) Tween20. (pH 2.2) 
Blocking buffer TBS/T, 5% (w/v) either non-fat dried 
milk or BSA 
Tris HEPES-SDS running buffer  100mM Tris HCl (pH 8.0), 1% (w/v) 
SDS, 100mM HEPES. 
Transfer Buffer 25mM Tris HCl, 192mM Glycine, 20% 
(v/v) ethanol. 
4X SDS sample buffer 200mM Tris HCl (pH 6.8), 40% (v/v) 
glycerol, 0.4% (w/v) Bromophenol, 8% 
(w/v) SDS. 
RIPA buffer 50mM Tris HCl (pH 7.4), 150mM 
NaCl,1mM EGTA. 
Lysis buffer RIPA buffer, 1mM PMSF, 1mM Na-
deoxycholic acid, 1% (v/v) NP40, 1mM 
Na3VO4, 2ug/ml Leupeptin  
1X TBE buffer 100mM Tris HCl, 0.9mM Boric acid, 
0.01mM EDTA. 
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TransLucent luciferase reporter 
vector, pTL-Luc 
TransLucent GAL4-BD controll 
vector, pTL-BD 
Panomics Inc. And  Caltag MedSystems 
Ltd, Cambridge, UK 
SignalSilence Control siRNA 
(Fluorescein Conjugate) 
New England BioLabs, Hitchin, 
Hertfordshire, UK 
 
2.5 Cell lines and culture 
 
The main cell line model used in this study, SMS-SB cells, was derived from a female 
patient  at the leukemic phase of acute lymphocytic leukaemia 265. These cells were 
cultured in RPMI-1640 medium supplemented with 10% (v/v) heat-inactivated foetal 
calf serum, 2mM fresh glutamine, (100U/ml) penicillin and (100µg/ml) streptomycin 
at 37º C and 5% CO2 in a humidified incubator. For experimental purposes, these 
cells were adapted and grown in protein-free hybridoma medium (PFHM) 
supplemented with (100U/ml) penicillin and (100µg/ml) streptomycin at 37º C and 
5% CO2 in a humidified incubator. The other two cell line models used in this study 
are called BAF03 and 697. BAF03 is a  murine pro-B cell line and was cultured in 
RPMI- 1640 medium with 50µM 2-ME (mercapto-ethanol) and 1ng/ml murine IL-3 
as well as 10% (v/v) heat-inactivated foetal calf serum, 2mM fresh glutamine, 
(100U/ml) penicillin and (100µg/ml) streptomycin 266. The 697 is a pre-B cell line 
extracted from a 12-year boy diagnosed with Acute Lymphocytic Leukaemia (ALL) 
267
. This cell line was cultured in RPMI-1640 medium supplemented with 10% (v/v) 
heat-inactivated foetal calf serum, 2mM fresh glutamine, (100U/ml) penicillin and 
(100µg/ml) streptomycin at 37º C and 5% CO2 in a humidified incubator. 
 
 64 
2.6 Proliferation assay 
 
2.6.1 Using tritiated thymidine  
 
Cells were harvested and washed twice in PFHM then plated at a density of 5000 
cells/100µl in each well of a 96-well flat bottom plate in PFHM. The plate was 
incubated for 72 hours at 37º C and 5% CO2 in a humidified incubator in the presence 
or absence of stimulants, soluble CD23, long peptide (LP); a peptide was derived 
from soluble CD23 and contains the RKC motif, vitronectin, SDF1-α and PDGF-AB. 
Then cells were pulsed with 0.3µCi/well (5.5 x 10-6  µmol) tritiated thymidine ([3 H ]- 
TdR) and re-incubated   at 37º C and 5% CO2 in a humidified incubator for 6 hours 
before harvesting and determination of incorporation by liquid scintillation 
spectrometry.  
 
2.6.2 Using Alamar blue 
 
Cells were harvested and washed twice in PFHM then plated at a density of 5000 
cells/100µl in each well in 96-well white flat bottom  plates in PFHM. In the case of 
697 and BAF03, cells were plated in PHFM medium supplemented with 1% (v/v) 
FCS. The plate was incubated for 48 hours at 37ºC and 5% CO2 in humidified 
incubator in the presence or absence of stimulants as noted above. In the case of using 
inhibitors, cells were incubated with either Tyrphostin AG490 or Tyrphostin AG1295 
for 3 hours at 37º C and 5% CO2 before plating. The plate then was incubated at the 
same conditions for a further 24 hours  after adding 10µl of Alamar blue dye (44 µM 
resazurin salt ) to each well 268. Plates were read in a fluorimeter at 544nm excitation 
filter and 590nm emission filter. 
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2.7 Flow Cytometry 
 
SMS-SB cells were harvested and washed three times in PBS buffer supplemented 
with 0.5% (w/v) BSA. Cells then were resuspended in the same buffer to a final 
density 5 x 106 cells/ml and 25ul of cells (1 x 105 ) was transferred to a 5ml tube for 
staining. Cells were Fc-blocked by treatment with 1ug of human IgG/105 cells for 15 
minutes at room temperature prior to staining. Cells then were incubated for 45 
minutes at 4ºC with 1µg of either FITC-conjugated or R-Phycoerythrin-conjugated 
mouse monoclonal antibodies raised against the human receptor or marker of interest. 
Following the incubation cells were washed twice in 4ml PBS buffer supplemented 
with 0.5% (w/v) BSA. Finally, cells were resuspended in 300µl of PBS buffer for 
flow-cytometric analysis.  
 
2.8 Protein Estimation assay (Bradford’s method) 
 
A protein concentration standard curve was plotted by using gradient concentrations 
(0, 5, 10, 15, 20,25,30,35 and 40 µg/ml) of BSA. Either standards or samples were 
diluted in dH2O before adding 1ml of Bradford’s reagent ( 0.01% (w/v) Coomassie 
Blue G250, 5.1% (v/v) H3PO4 and 5% (v/v) Ethanol). Samples and standards were 
incubated at room temperature for 10 minutes and the light absorption was detected 
by spectrophotometry at A595 nm. The unknown protein concentrations were each 
determined in accordance with the linear range of the resulting standard curve.  
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2.9 Antibody arrays 
    
2.9.1 Principle of the assay 
 
This assay is intended to analyze the phosphorylation profiles of kinases and their 
protein substrates. It is a simultaneous detection of the levels of phosphorylation of 46 
kinase phosphorylation sites, using capture and control antibodies spotted in duplicate 
on nitrocellulose membranes. These antibodies catch their targets in the  lysates 
during overnight incubation. The captured targets then will be visualized by 
biotinylated detection antibodies. Some signals will produced when the membrane 
developed by streptavidin-HRP followed by chemiluminescent detection reagents. 
Each capture spot corresponds to the amount of phosphorylated protein bound.   
 
2.9.2 Procedures   
 
SMS-SB cells were harvested and washed twice in PFHM and adjusted to a density of 
107 cells/ml in PFHM. Four universal tubes each contained 107 cells/ml;  one of them 
was a control without treatment and at 0  time,  the rest of them were treated by either 
5µg/ml of long peptide or 250ng/ml of sCD23 and incubated at 37º C and 5% CO2 in 
a humidified incubator for 5, 10 and 20 minutes time course. The cells were washed 
twice in ice-cold phosphate-buffered saline to quench the reaction. After the second 
wash the supernatants were discarded and the pellets were resuspended in 1ml of lysis 
buffer supplied with the antibody array kit. Samples then were incubated on ice for 30 
minutes on rocking platform at 20xg, then centrifuged at 14000 xg for 5 minutes at 
4ºC. Supernatants were then transferred into a clean 1.5 ml microcentrifuge tube. The 
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Bradford protein estimation was carried out for the soluble fractions before using 
them for the array protocol. Each membrane to be used was blocked by incubating in 
1ml of array buffer which is supplied with the array membranes for 1 hour on a 
rocking platform. The lysates were then diluted to 120µg/ml using the array buffer 
and applied onto the blocked membranes. Membranes then were incubated overnight 
at 4ºC. On the following day membranes were washed three times by 1x wash buffer 
for 10 minutes each. After the third wash each membrane was incubated with 1ml of 
array buffer containing 20µl of detection antibody cocktail for 2 hours at room 
temperature on a rocking platform. Membranes were washed again three times by 1x 
wash buffer for 10 minutes each followed by incubating with streptavidin-HRP for 30 
minutes at room temperature on a rocking platform. Three washes were applied to the 
membranes with 1x wash buffer for 10 minutes each. Finally, membranes were 
developed by the chemiluminescence substrate for three minutes and exposed several 
times for different periods on the X ray film.  
 
2.10 Western blotting 
 
SMS-SB cells were harvested and washed twice with protein-free media (PFHM) and 
adjusted to a density of 5 × 106 cells/ml. Two ml of cells  either treated or untreated 
were washed in ice-cold  radioimmunoprecipitation assay (RIPA) buffer (50mM Tris-
HCl pH 7.4, 150mM NaCl, 1mM EGTA) and lysed in RIPA buffer containing (1mM 
Na3VO4, 1% (v/v) NP40, 1mM Na deoxycholate, 1mM PMSF and 2µg/ml 
Leupeptin). Protein concentrations were estimated by Bradford’s method. The same 
protein concentration of lysates was loaded per lane on a 4-12% NuPAGE Novex Bis-
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Tris gradient gels using the MES buffer; both were supplied from Invitrogen. Proteins 
were separated on the gels at 180V and 70mA for 1 hour. Separated proteins were 
transferred onto nitrocellulose membrane in the presence of transfer buffer at 30V and 
220mA for 90 minutes using (XCell SureLock) blotting system supplied from 
Invitrogen. The membrane then was blocked by TBS/T buffer containing either 5% 
non fat milk or BSA according to the antibody supplier protocol and then rinsed once 
with TBS/T buffer. The membrane was incubated with primary antibody for either 
four hours at room temperature or overnight at 4 º C according to the supplier protocol 
and washed by TBS/T three times for 5 minutes each before incubating for one hour 
with HRP-linked secondary antibody. After that the membrane was washed three 
times by TBS/T buffer for 5 minutes each. Ultimately, the membrane was developed 
by using the chemiluminescence substrate and exposed several times with different 
periods on the X ray film.  
 
2.11 Immunoprecipitation 
 
SMS-SB cells were harvested and washed twice with PFHM and adjusted to a density 
of 5 × 106 cells/ml. Two ml of cells  either treated or untreated were washed twice in 
ice-cold PBS buffer and lysed in 500µl of HEPES buffer containing (1% (w/v) Octyl-
β-D-glucopyranoside, 0.5% (v/v) Protein inhibitor cocktail). The protein 
concentrations were estimated by Bradford’s method. 400µl containing 400µg of 
protein from each sample and the control was incubated for 30 minutes with  4µg 
antibody against the target protein in a spin column purchased from Millipore which  
contains precipitation slurry, and 1µg antibody capture affinity ligand supplied with 
the kit. The spin columns were washed twice with 1x wash buffer. Target proteins 
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were eluted by applying three cycles of adding 70µl of 2x elution buffer and 
centrifugation at  2400 xg for 30 seconds. The eluates were collected after each 
elution cycle. The eluates were run on a 4-12% NuPAGE Novex Bis-Tris gradient 
gels using the MES buffer supplied from Invitrogen and immunoblotted as described 
in western blotting section. 
 
 
2.12 Electrophoretic-Mobility Shift Assay (EMSA) 
 
SMS-SB cells were harvested and washed twice with PFHM and adjusted to a density 
of 5 × 106 cells/ml. Two ml of cells either treated or untreated during the time course 
were washed once with 5ml of ice-cold PBS buffer containing phosphatase inhibitors 
supplied with the nuclear extraction kit (purchased from Active Motif Company). 
Samples were spun down at 4ºC for 5 minutes at 2400 xg. The pellets were lysed by 
500µl hypotonic buffer supplied with the kit and incubated for 15 minutes on ice on a 
rocking platform at 20 xg. Samples were vortexed at high speed each with 25µl 
detergent supplied with the kit and centrifuged at 14000xg for 30 seconds at 4ºC. 
Pellets were resuspended in 50µl complete lysis buffer and incubated for 30 minutes 
on ice on a rocking platform at 20 xg. The suspensions were centrifuged at  4ºC for 10 
minutes at 14000xg. The supernatants were  collected and the protein concentration 
was measured by Bradford’s method. Three micrograms of each sample was 
incubated for 5 minutes at room temp with (1µl of STAT5b biotinylated probe 
[CAGAATTTCTTGGGAAAGAAAAT], 1µg poly d(I-C), 2µl of 5x binding buffer 
and 3µl of  nuclease-free water ). Mixtures were incubated at 15°C for 30 minutes in a 
thermal cycler. Samples were mixed with 1 µl of loading dye and run on 6.0% non-
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denaturing polyacrylamide gel with pre-chilled  0.5X TBE. Separated protein/DNA 
complexes on the gel were transferred onto N+ nylon membranes purchased from 
Amersham company. Membranes were baked at 80ºC for an hour for protein/DNA 
cross linking and blocked for 15 minutes in a blocking buffer. Membranes were 
incubated for 30 minutes with streptavidin- HRP followed by three washing cycles 
with 1x wash buffer for 8 minutes each. At the last step membranes were incubated in 
detection reagent supplied with the kit for 5 minutes and then for 5 minutes again  
with the chemiluminescence substrate before  exposing several times for different 
periods on the X ray film.  
 
2.13 Calpain activity assay 
 
SMS-SB cells were harvested and washed twice with PFHM and adjusted to a density 
of 2 × 106 cells/ml. For the short term stimulation study, cells were divided into three 
50ml tissue culture tubes each containing 6ml of cellular suspension; one was a 
control without treatment, one was treated with 1.8nM vitronectin and one treated 
with 33uM long peptide. The three tubes were incubated at 37º C and 5% CO2 in a 
humidified incubator.  From the control tube 1ml of cells was immediately incubated 
on ice as  time 0 control. One ml from each tube was removed and immediately  
incubated on ice at each time point (3,15,25 and 40 minutes). However, for the long 
term stimulation study the same procedure was followed but the differences were the 
time points which were 30 minutes, 1, 2 and 4 hours. Samples were then centrifuged 
at 14000xg for 30 seconds at 4ºC. Supernatants were discarded and the pellets were 
resuspended in 100µl of extraction buffer supplied with the kit and incubated on ice 
for 20 minutes with gentle mixing by tapping from time to time. Samples then 
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centrifuged at 10000xg for 1 minute at 4ºC. Supernatants were collected and the total 
protein was estimated by using Bradford’s reagent. In 96-well white flat bottom plate 
samples were plated in 60µg total protein/ 85µl of extraction buffer.10µl of 10x 
reaction buffer was added into each well followed by adding a specific Calpain 
substrate, which is called AC-Leu-Leu-Tyr-7-amino-4-Trifluoromethylcoumarin (AC-
LLY-AFC).The plate was incubated for in the dark at 37º C. Fluorescent activity was 
measured by a fluorimeter at 355nm excitation filter and 505nm emission filter.   
 
2.14 Control for siRNA Transfection efficiency 
 
SMS-SB cells were harvested and washed twice with PFHM and adjusted to a density 
of 3 × 105 cells/ml. In a 24 well tissue culture plate, 250µl of cells were plated in each 
well. The oligo/Transfection reagent complex was formed in three different ratios to 
examine transfection efficiency and toxicity, 3µl of Control siRNA (Fluorescein 
Conjugate) were diluted in 50µl PFHM and mixed with either 1µl,2.5µl or 4µl of 
Transfection reagent. The mixtures then were vortexed and incubated at room 
temperature for 15 minutes before adding each of them to the cells in the appropriate 
well. The plate then was incubated at 37º C and 5% CO2 in a humidified incubator. 
After 48 hours cells were harvested and washed twice with PBS and resuspended in 
500ul of PBS. Finally, cells were assayed  by flowcytometry.  
 
2.15 Reporter gene experiments  
 
The plasmid/Transfection reagent complex was formed by diluting 3µg of 
pGL4.34[luc2P/SRF-RE/Hygro] Vector in 180µl PFHM without antibiotics and 
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mixed with 8µl of X-tremeGENE HP Transfection reagent. The mixture was 
incubated for 25 minutes at room temperature. In terms of the STAT5 reporter vector 
assay, the complex was formed by diluting 1.5µg TransLucent GAL4-STAT5B 
(TAD) fusion protein expression vector with 1.5µg of TransLucent luciferase reporter 
vector in 180µl PFHM without antibiotics and then adding 8µl of X-tremeGENE HP 
Transfection reagent. Meanwhile, SMS-SB cells were harvested and washed twice 
with PFHM and adjusted to a density of 3 × 105 cells/ml. 90µl of cells/well were 
plated in  96-well white flat bottom  plate and mixed with 10µl of 
plasmid/Transfection reagent complex. The plate was incubated at 37º C and 5% CO2 
in a humidified incubator for 48 hours before adding stimulants (sCD23, LP and 
vitronectin) and re incubating at the same conditions for 6 hours as described in 
Chapter 4 . Cells then were lysed and treated with luciferen substrate. The luciferase 
activity was estimated in three minutes after adding the substrate by illuminometer .    
 
2.16 Data analysis 
 
Results are shown as mean plus or minus standard error of the mean (SEM) of 
triplicate experiments. Data were normalized by dividing each result by the control. 
Statistical comparison was performed using the Student paired t test. The minimal 
level of significance was P<0.05. Each result represents an accumulated data for at 
least three experiments that were carried out in three different dates unless otherwise 
stated. In terms of western blots, EMSA blots and the antibody membranes the data 
were quantitated by using a software called Image J (National Institutes of Health), to 
estimate the optical density of each experimental sample.   
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3. SMS-SB cells growth in response to 
different ανβ5 integrin ligands and other 
proteins related to B-cell progenitors 
growth.  
 
3.1 Introduction 
 
There are several factors which stimulate growth and maturation of B-cell precursors 
during their development in bone marrow. As mentioned in the introduction chapter, 
stromal-derived factor (SDF1) is one of the important growth and survival  factors for 
B-cell progenitors which integrates with other growth factors such as interleukin-4, 
interleukin-7 and Platelet-derived growth factor (PDGF) 269, 270, 271. In this study, the 
cell line model used is SMS-SB, which is a line derived from a nine-year old girl 
diagnosed as an acute lymphocytic leukaemia patient 265. These cells express the 
cytoplasmic µ heavy chains but do not secrete them 265. In addition, they do not 
express IgM and light chains 265. Phenotypically, SMS-SB cells seem to be located 
between two stages of B-cell progenitors development;  pro-B cell and pre-B cell 265.  
On the other hand, CD23 is highly expressed on chronic lymphocytic leukaemia cells 
but  was not detected in acute lymphocytic leukaemia cells 272, 273. However, soluble 
CD23 was highly increased  in the serum of  42  chronic lymphocytic leukaemia 
patients  comparing with 32 normal individuals 274. In terms of SMS-SB cells, they do 
not express CD23, CD11b-CD18, CD11c-CD18 and CD21 275. Furthermore, CD23 
sustains bcl-2 protein levels in SMS-SB cells in order to prevent apoptosis when they 
are cultured in low cell density 275. This action occurs when soluble CD23 binds the 
ανβ5 integrin 95. Although ανβ5 integrin binds its specific ligands such as vitronectin 
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and fibronectin through an RGD motif, it binds CD23 via a tripeptide motif Arg-Lys-
Cys (RKC) located close to the C-type lectin domain of CD23 95. 
 The main purpose of this chapter is to investigate the ability of different ligands to 
stimulate SMS-SB growth at the minimal density, and in addition, to find out which 
signalling targets are involved in the action of sustaining SMS-SB cell growth.  
3.2 Results 
3.2.1 Phenotypic characterisation of SMS-SB cell line 
 
There are several markers used to identify the B-cell development stages. As 
mentioned previously SMS-SB cells are B-cell progenitors extracted from an acute 
lymphocytic leukaemia  patient. The aim of this experiment is to identify the 
development stage that SMS-SB cell represents and to investigate the expression of 
growth-related  receptors which this study will focus on, mainly the αVβ5 integrin as 
well as PDGFR and CXCR4 ( the SDF-1 receptor ).  
Figure 3.1 clearly shows that SMS-SB cell express CD19 a major determinant of B-
cell lineage and, to a lesser extent, CD45. However, SMS-SB cells do not express 
CD34, a marker for the very early stage of haematopoietic cell development. In 
addition, these cells do not express some pre-B cell markers such as µ-chain, or CD10 
and they do not express CD5 which is most likely a marker of T-cell and human foetal 
lymphoid tissues 276 as shown in figure 3.1. In terms of the receptors that this project 
is to focus on, SMS-SB cells do not express CD23 and β3 integrin but, they clearly do 
express CXCR4,  PDGF receptor and αVβ5 integrin as shown in figure 3.1. These 
data suggest that SMS-SB cell is a Pro-B cell and probably at the late  developmental 
stage of  pro-B cell because they also express cytoplasmic µ-chain, ( data not shown ) 
265
 . 
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Figure 3.1  Phenotypic characterization of SMS-SB cell. SMS-SB cells were harvested and 
washed twice with PBS buffer supplemented with 0.5% (w/v)BSA and adjusted at 5x106 
cell/ml. 25µl of cells were incubated individually with 10µ l of either R-Phycoerythrin or 
FITC conjugated antibodies to CD23, CD19, CD5, CD10, CD45, µ-Chain, β3 integrin, αVβ5 
integrin, PDGF receptor, CXCR4 or CD34. The negative controls were Mouse IgG1-PE 
conjugated and Mouse IgG1-FITC conjugated. Shown expressing was assessed by using 
FACS system. FACS staining for the negative controls is shown as blue shaded area and for 
the each MAb is shown as a green line. These data are representative of at least three 
independent staining experiments.  
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3.2.2 SMS-SB cell growth is cell density dependent. 
 
There are two purposes for this experiment. The first aim is  to investigate the effect 
of cell density on SMS-SB cell growth which has published by our laboratory already 
271
. According to Tsai et. Al (1994). SMS-SB cells express and release PDGF as an 
autocrine factor which is also implicated to sustain cell growth at high density. The 
other goal of this experiment is to compare the accuracy of Alamar blue, a fluorescent 
dye and tritiated thymidine incorporation in the context of growth estimation.  
Briefly, Alamar blue is a solution of resazurin salt added in a non-fluorescent 
oxidized/blue form, which undergoes reduction caused by oxygen consumption 
metabolism of living cells 277. The reduced form of the resazurin salt is a 
fluorescent/pink, which is called resorufin, and can be measured by a fluorimeter with 
544nm excitation filter and 590nm emission filter 277. The tritiated thymidine [3H]-
TdR proliferation assay depends upon measuring the amount of [3H]-TdR 
incorporated into DNA by using a scintillation counter 278.  
Panel (a) in figure 3.2 clearly shows that SMS-SB cells proliferate about eight-fold 
when plated at 5X105 cell/ml compared with those plated at 5X104 cell/ml, about five-
fold when plated at 2.5X105 cell/ml, and about three-fold when plated at 1X105 cell/ml 
compared with those plated at 5X104 cell/ml. These data were collected by using the 
thymidine incorporation method. Statistically, the growth increase of cells was 
significant over the three biological replicates in which the P value was less than 0.05. 
 Panel (b) in figure 3.2 shows similar data using Alamar blue. Surprisingly, Alamar 
blue method gives a similar reading to [3H]-TdR method in which P values of three 
biological replicates are less than 0.001. In general, these data suggest that SMS-SB 
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cell growth is cell density-dependent and that either Alamar blue or [3H]-TdR 
corporation can be used to detect proliferation accurately. 
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Figure 3.2 Density dependent SMS-SB cell growth. SMS-SB cells were 
cultured at the indicated cell densities for 48 hours at 37ºC and 5% CO2.(a) Cells 
were pulsed for the final six hours with 0.3µCi/well [3H]-TdR and harvested onto 
filter mats for liquid scintillation spectrometry.(b) Cells were incubated for 24 
hours further with 4.4uM resazurin salt (Alamar blue) and the fluorescence was 
estimated in a fluorometer at 544nm excitation filter and 590nm emission filter. ** 
P < 0.001, * P < 0.05 versus corresponding 5x104 cell/ml. (These data represent three 
independent experiments for each). 
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3.2.3 Soluble CD23 and LP stimulate proliferation of SMS-
SB cells while vitronectin does not 
 
In this experiment, three different stimuli were used to investigate the role of αVβ5 
integrin in SMS-SB cell growth. LP is a synthetic peptide derived from soluble CD23 
with a length of 15 amino acids and contains the RKC motif, a motif via which 
soluble CD23 binds to the αVβ5 integrin. The third ligand is Vitronectin, one of the 
matrix ligands which binds to the αVβ5 integrin via its RGD motif. 
Figure 3.2 clearly shows that SMS-SB cell growth is dose-dependent when cells are 
stimulated by either sCD23 or LP (the RKC motif-containing ligands). In panel (a) 
SMS-SB cell growth was increased about 10-fold following stimulation with LP at a 
concentration of 66µM (10µg/ml) and about 9-fold with 33µM (5µg/ml). Both of 
these stimulations were statistically significant different from unstimulated controls (P 
values were less than 0.005 for three independent experiments). A similar trend was 
obtained using sCD23 stimulation  ( panel (b) ) which gives about 8 fold stimulation 
when added at 20nM (500ng/ml) and about 6 fold with 10nM (250ng/ml). Data 
analysis for three independent experiments shows that both of these stimulations are 
significant ( P values are less than 0.005 and 0.05, respectively ). On the other hand, 
SMS-SB cells did not respond to increasing concentrations of Vitronectin 0.36-3.6nM 
(50-500ng/ml) as shown in figure 3.2 panels (c). These data suggested that sCD23 
(the RKC containing ligand) could stimulate αVβ5 integrin to modulate B-cell 
precursor growth whereas matrix ligands (the RGD containing ligands) could not. 
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Figure 3.3 αVβ5 integrin mediates growth of SMS-SB cells when ligated by sCD23 
and LP (a peptide derived from sCD23 contains RKC motif), but not vitronectin. 
SMS-SB cells (5×104 cells / ml in protein-free medium) were stimulated  with the 
indicated concentrations of stimulants for 48hr, then processed for Alamar Blue 
fluorescence (sCD23 and Vitronectin treated plates ) or were pulsed with 0.3µCi/ well 
tritiated thymidine (LP treated plates ).** P < 0.005, * P < 0.05 versus corresponding 
untreated cells. (These data represent three independent experiments). 
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 3.2.4  Stromal cell –derived factor 1α (SDF1α) Stimulates 
SMS-SB cells proliferation. And enhances SMS-SB cells 
growth stimulated by LP. 
 
Stromal cell-derived factor-1 plays an important role in B-cell development 124.The 
following experiments were carried out to determine to what extent SDF-1 itself can 
stimulate SMS-SB cell growth, and also to investigate  the effect of SDF-1 on cell 
growth stimulated by LP. Normally, the plasma levels of SDF-1 are between 8-
20ng/ml 279. The SDF-1 levels either in peripheral blood or bone marrow are 
dramatically increased in AML, HIV infections and Non-Hodgkin’s lymphomas  279, 
280,
 
281
.   
Figure 3.4 Panel (a) shows that a modest increase of  SMS-SB cell growth is 
correlated with increasing concentrations of added SDF-1α. This growth increase 
peaked at 250ng/ml (31.25nM) SDF-1α, and was statistically significant ( P  value 
was less than 0.05 for three independent experiments ) compared to the cells were 
grown without treatment.  
In Panel (b), SDF-1α strikingly increases the cell growth stimulated by  5ug/ml 
(33µM) LP. Roughly, about a 20% further growth increase was observed when cells 
were co-stimulated by either 100ng/ml (12.5nM)  or 250ng/ml (31.25nM) SDF-1α,  
the differences were statistically significant ( P values were less than 0.05 for three 
independent experiments ) compared to the cells were stimulated with LP alone.These 
data suggested that SDF-1α enhances cell-growth stimulated by LP. 
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Figure 3.4  SDF1α  stimulates growth of SMS-SB cells and enhances SMS-SB cells 
proliferation stimulated by LP. SMS-SB cells (5×104 cells / ml in protein-free medium). 
Panel (a) cells were stimulated with the indicated concentrations of SDF1α for 48hr, and then 
pulsed with 0.3µCi/ well tritiated thymidine. * P < 0.05 versus corresponding untreated cells. 
Panel (b) cells were cultured with either 31.25nM (250ng/ml) of SDF1α or 33µM (5µg/ml) of 
LP or with 5µg/ml of LP plus increasing concentrations of SDF1α for 48 hours, then 
processed for Alamar Blue fluorescence. ** P < 0.005 versus corresponding untreated cells.   
• P < 0.05 versus corresponding cells stimulated with LP alone. (These data represent three 
independent experiments). 
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3.2.5  Platelet Derived Growth Factor (PDGFAB) Stimulates 
SMS-SB cells proliferation. And enhances SMS-SB cells 
growth stimulated by LP. 
 
There are five different isoforms of PDGF ; PDGFAA, PDGFBB, PDGFCC, PDGFDD 
and PDGFAB 146, 155, 156. Many studies  have been published over the last two decades 
demonstrates that PDGF family members are implicated in stimulating the growth of  
various cancers, angiogenesis, atherosclerosis and liver fibrosis  282, 283, 284, 285. In 
leukaemias, PDGFAB is implicated in AML cell growth, and is also expressed in 
CML, pre-B acute lymphocytic leukaemias ( particularly SMS-SB cells ) and chronic 
eosinophilic leukaemia 286, 271, 287.  
The purpose of this experiment was to investigate the role of PDGFAB as a growth 
factor for SMS-SB cells in sustaining cell growth. The other aim was also to examine 
any synergistic effect of  
 
PDGFAB with soluble CD23, which is represented by LP. 
Figure 3.5 panel (a) shows that SMS-SB cell growth gradually increased with 
increasing PDGFAB dose. The statistical analysis for three independent experiments 
shows that there is a significant growth  increase ( P  value was less than 0.005 ) at 
250ng/ml (82.5nM), with an increase of  three-fold compared to the cells were grown 
without treatment.  
In terms of co-stimulation, panel (b) PDGF has enhanced by more than 20% cell-
growth stimulated by 5µg/ml LP. This additional growth increase was significant at 
100ng/ml and 250ng/ml of PDGFAB (P values were less than 0.05 and 0.005, 
respectively, for three independent experiments) compared to the cells stimulated with 
LP alone. 
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Figure 3.5 PDGFAB stimulates growth of SMS-SB cells and enhances cell growth 
stimulated by LP. SMS-SB cells (5×104 cells / ml in protein-free medium), panel (a) 
cells were stimulated with the indicated concentrations of PDGFAB for 48hr, then pulsed 
with 0.3µCi/ well tritiated thymidine. ** P < 0.005 versus corresponding untreated cells. 
Panel (b) cells were cultured with either 8.3nM (250ng/ml) of PDGF-AB or 33µM 
(5µg/ml) of LP or with 5µg/ml of LP plus increasing concentrations of PDGF-AB for 48 
hours, then processed for Alamar Blue fluorescence. ** P < 0.005, * P < 0.05 versus 
corresponding untreated cells. • P < 0.05, •• P < 0.005 versus corresponding cells 
stimulated with LP alone. (These data represent three independent experiments). 
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3.2.6 Soluble CD23 and LP stimulate the phosphorylation 
of  different kinase substrates 
 
The previous data raised the question of how LP or soluble CD23 stimulates the cell 
growth and which signalling pathway is recruited by the αVβ5 integrin as a 
consequence of its interaction with specific ligands.  
One of several recent methods for screening cell signalling pathways is an antibody 
array technique. This method depends on a group of antibodies being spotted 
individually on a nitrocellulose membrane in duplicate. These antibodies are raised  
against different human cell signalling proteins in phosphorylated form.  
This experiment revealed that either soluble CD23 or LP activates phosphorylation of  
several kinases and signal transducers. Figure 3.6 shows the antibody array blots and 
their densitometric analysis for lysates of SMS-SB cells either untreated, as a control, 
or treated with either sCD23 or LP for a 20 minutes  time course. Both stimuli 
increase phosphorylation of STAT5a/b at Tyrosine 699 which is clearly observed after 
five minutes of stimulation and sustained over the 20 minutes time course. The other 
signal transducer was  STAT2 which is phosphorylated at Tyrosine 689. Furthermore, 
both ligands stimulated the phosphorylation of Src at Tyrosine 419 but with LP that 
event came five minutes earlier. In addition, a Src family member (Yes) is 
phosphorylated at Tyrosine 426 and AMPKα2 at Threonine 172. These data might 
open a broad story  involving different signaling pathways for different purposes such 
as growth, survival or anti apoptosis. 
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Figure 3.6  sCD23 and LP stimulate different signalling targets. SMS-SB cells were 
stimulated with either the CD23-derived LP, (33µM) or with sCD23 itself (10nM) for the 
indicated times and aliquots of lysates added to individual antibody arrays and binding 
determined by ECL Panels b) and c). Panel a) shows the map of the target substrates printed 
on a nitrocellulose membrane and panel d) shows the densitometry data. 
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3.3 Conclusion 
 
 
The data presented in this chapter clearly indicate that SMS-SB cells express the 
αVβ5 integrin, PDGF receptor and CXCR4, which are related to the cell growth as 
demonstrated in the first chapter of this thesis. In addition, these cells express CD19, 
one of the common B-cell precursor markers; however, they do not express the µ-
heavy chain on the cell surface which suggests that these cells might represent the 
pro-B cell development stage. Consequently, figure 3.3, 3.4 and 3.5 show that these 
receptors are related to the cell growth after stimulating them with PDGFAB, SDF1-α, 
sCD23 and LP. Furthermore, figure 3.2 has also shown that SMS-SB cell growth is 
density dependent. These data are strongly compatible with the data published by 
Borland, G. et al, Tsai, L.H. et al and Acharya, M. et al. 95, 123, 271. 
In order to investigate how the αVβ5 integrin is involved in cell growth stimulation, 
the antibody array data demonstrated in figure 3.6 show that both sCD23 and LP 
stimulate multiple signalling targets such as STAT5, STAT2, c-Src, c-yes and 
AMPKα2 which poses several questions about the link between STAT5 
phosphorylation and cell proliferation, and about how the αVβ5 integrin can induce 
the phosphorylation of STAT5. 
Therefore, the next chapter will concentrate on confirming the antibody array data and 
on investigating STAT5 activity as well as focusing on investigating the relationship 
between the αVβ5 integrin stimulation and the phosphorylation of STAT5. 
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4. Soluble CD23 and LP activate Jak2/ 
STAT5a/b pathway due to a unique 
PDGFRβ-αVβ5 integrin association. 
 
4.1 Introduction   
 
STAT5a/b
 
is a heterodimeric protein composed of STAT5a (94KDa) and STAT5b 
(92KDa). The difference between these two proteins is in the 12 C-terminal amino 
residues 288. STAT5a and STAT5b genes are located on chromosome 17 192. Several 
studies over the last ten years have revealed some critical roles of STAT5a/b in the 
immune system. STAT5a/b is required for T-cell proliferation, activation and 
tolerance mainly in response to IL-2 289, 290, 291. In addition, STAT5a/b is involved in 
haematopoietic cell adhesion and migration 292.  
On the other hand, the Jak2/STAT5 signalling pathway is implicated to play a crucial 
role in cell survival, proliferation and apoptosis of several leukaemias in response to a 
wide range of cytokines and growth factors 293, 294, 295. 
This chapter will concentrate mainly on investigating the role of the Jak2/STAT5a/b 
signalling pathway in SMS-SB cell growth stimulated by either sCD23 or LP to 
validate the data obtained from the antibody array experiments demonstrated in the 
previous chapter. The other important purpose for this chapter is to investigate how 
does the αVβ5 integrin contribute to the Jak2/STAT5ab signalling pathway. 
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4.2 Results 
 
4.2.1 αVβ5 integrin mediates STAT5 phosphorylation due 
to its binding to different ligands 
 
The data later are based on simple western blotting technique. There are two purposes 
for these experiments. The first aim is to validate the data that was obtained from the 
antibody array experiment. The second aim is to investigate the difference between 
different ligands that bind to αVβ5 integrin via different binding motifs in activating 
STAT5 phosphorylation. Three ligands in this experiment have been tested, soluble 
CD23 and LP which both bind by the RKC motif, and vitronectin which binds to the 
αVβ5 integrin via the RGD motif. 
Figure 4.1 clearly shows that LP activates the phosphorylation of STAT5 at tyrosine 
699 after five minutes of stimulation and sustains that event over the 20 minutes time 
course. Similar data were observed with stimulating the cells with soluble CD23 
instead of LP as shown in figure 4.2. In contrast, as shown in figure 4.3 vitronectin 
does not show any significant stimulation. These data suggest that the αVβ5 integrin 
activates STAT5 phosphorylation when it binds to the soluble CD23 but not when the 
vitronectin binds.   
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Figure 4.1 LP Stimulates the αVβ5 integrin to promote STAT5b phosphorylation.  
Lysates were extracted from cells either stimulated by 33µM LP or without stimulation for the 
indicated time course and, after western blotting, probed with antibodies to phosphorylated 
STAT5b then stripped and re-probed with antibodies to STAT5b protein Panel a). Panel b) is 
the densitometric analysis for the phospho-STAT5/STAT5 ratio demonstrated. The other 
Panels c)and d)  are the densitometric analysis for the phospho-STAT5/STAT5 ratios for  
another blots of two individual experiments have been carried out in different weeks. Black 
bars represent phospho-STAT5/STAT5 ratios in stimulated cells in all cases, and the white 
bars represent the unstimulated cells. 
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Figure 4.2 Soluble CD23 Stimulates the αVβ5 integrin to promote STAT5b 
phosphorylation.  Lysates were extracted from cells either stimulated by 10nM sCD23 or 
without stimulation for the indicated time course and, after western blotting, probed with 
antibodies to phosphorylated STAT5b then stripped and re-probed with antibodies to STAT5b 
protein Panel a). Panel b) is the densitometric analysis for the phospho-STAT5/STAT5 ratios 
demonstrated. The other Panels c)and d) are the densitometric analysis for the phospho-
STAT5/STAT5 ratios for another blots of two individual experiments have been carried out in 
different weeks. The white bars represent the unstimulated cells while the black bars represent 
the stimulated cells. 
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Figure 4.3 Vitronectin does not clearly stimulate the αVβ5 integrin to promote STAT5b 
phosphorylation. Lysates were extracted from cells stimulated by 1.8nM vitronectin or 
without stimulation for the indicated time course and, after western blotting, probed with 
antibodies to phosphorylated STAT5b then stripped and re-probed with antibodies to STAT5b 
protein Panel a). Panel b) is the densitometric analysis for the phospho-STAT5/STAT5 ratios 
demonstrated. The other Panels c)and d) are the densitometric analysis for the phospho-
STAT5/STAT5 ratios for another blots of two individual experiments have been carried out in 
different weeks. The white bars represent the unstimulated cells while the black bars represent 
the stimulated cells. 
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4.2.2 Both soluble CD23 and LP strongly induce STAT5 / 
DNA binding but vitronectin causes a smaller induction 
 
 
STAT5a/b is a member of  the STAT proteins which are transcription factors playing 
different biological roles in cell survival, growth and apoptosis 227, 191. The active form 
of STAT5b interacts with the DNA at specific binding sequence 
CAGAATTTCTTGGGAAAGAAAAT  296, 297. 
 Therefore to test binding activity, the Electrophoretic-Mobility Shift Assay (EMSA) 
was used to test the transcription factor/DNA binding activity by using the specific 
binding sequence for probing STAT5 binding.   
Figure 4.4 clearly shows that the STAT5/DNA interaction is strongly enhanced after 
15-30 minutes of stimulating cells with either 33µM LP or 10nM soluble CD23 
compared to untreated cells. In contrast, a minimal STAT5/DNA interaction activation 
was observed using vitronectin as stimulant. These data give an additional 
confirmation of the antibody array data and nicely fit the results obtained by the 
western blotting.  
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Figure 4.4 Stimulation of SMS-SB cells by sCD23, LP and vitronectin activate 
STAT5b/DNA binding activity. (a) Nuclear extracts (3µg) of either stimulated or un 
stimulated  SMS-SB cells were mixed with biotin-labelled STAT5 probe and protein/DNA 
complexes were separated on a non-denaturing gel, transferred to a nylon membrane and 
detected using strepatvidin-HRP. (b) The band intensities were quantitated by densitometry for 
the demonstrated gel. (c) and (d) represent the band intensities for two further experiments. 
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4.2.3 Both soluble CD23 and LP induce STAT5b 
transcriptional activity 
 
 
In this experiment, SMS-SB cells have been transiently co-transfected with two 
plasmids,  an expression vector containing a trans-activation domain (pTL-TAD) of 
STAT5b fused to the Gal4-DNA binding domain (DBD). The other vector is a Gal4-
responsive luciferase plasmid (pTL-Luc). Therefore, when STAT5b becomes activated 
it will activate luciferase expression via inducing Gal4 expression. Ultimately, the 
STAT5b transcriptional activity is measured by estimating luciferase activity in a 
luminometer. Cells were then stimulated with either 33µM LP, 10nM sCD23 or 1.8nM 
vitronectin 48 hours following the transfection. 
The data shown in figure 4.5 clearly indicate a significant luciferase activation caused 
by both LP and sCD23 which abut double of luciferase activation compared with 
untreated co-transfected cells. 
On the other hand, vitronectin does not give a significant response which is compatible 
with the previous data. So far, the data obtained from the previous work suggest that 
the αVβ5 integrin modulates the activation of STAT5b via it binding to the soluble 
CD23 and LP the RKC containing ligands. However, these data raise two important 
questions about the role of STAT5 in the cell-growth stimulated by both ligands and 
how the αvβ5 integrin can mediate the STAT5 phosphorylation.  
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Figure 4.5 LP and sCD23 clearly stimulate STAT5b responsive reporter vector but 
vitronectin (Vn) causes less stimulation. SMS-SB cells were transiently co-transfected by 
(pTL-luc) and  (pTL-TAD) STAT5b responsive vector. Cells were incubated for 48 hours at 
37oC and 5%CO2 followed by adding the stimuli; 1.8nM Vn (blue bar), 33µM LP (black bar) 
and 10nM sCD23 (grey bar). After 6 hours further incubation, the luciferase activity was 
assessed by using luciferase substrate in a plate illuminometer. (These data are representative 
of three independent experiments).   
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4.2.4 LP and Soluble CD23 stimulate the phosphorylation 
of  Jak2 while vitronectin shows less  stimulation 
 
There are several Jak/STAT pathways playing different biological roles in response to 
various cellular stimuli. STAT5 usually lies downstream of two Jak isoforms, Jak2 and 
Jak3 depending on the ligand, cell type and the receptor for ligand. However, any Jak 
family member needs to be phosphorylated in order to phosphorylate the downstream 
target. The phosphorylation of Jak2 at tyrosine 1007/1008 is potentially required for 
Jak2 auto- or trans-phosphorylation and for Jak2 kinase reactions 298 
Therefore, the aim of this experiment is to investigate the effect of LP, sCD23 and 
vitronectin on Jak2 phosphorylation for answering the question of how STAT5 is 
eventually phosphorylated by these ligands due to their interaction with the αVβ5 
integrin. 
Figure 4.6 shows a western blot of cellular extracts of either treated or untreated cells 
during a 20 minutes time course which has been probed by anti-phospho                   
Jak2 Y1007/1008 which is also stripped and reprobed by anti-total Jak protein. As clearly 
shown in this figure, LP significantly increases Jak2 phosphorylation levels comparing 
with the control (untreated cells). Similarly, increased levels are observed with soluble 
CD23 stimulation but not with vitronectin. 
The data shown in figure 4.6 suggest that the trend of Jak2 phosphorylation might fit 
the trend of STAT5 phosphorylation in response to the same αVβ5 integrin-ligands. 
However, further investigation needs to be done to disclose whether Jak2 is the STAT5 
kinase or not. 
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Figure 4.6 Stimulation of SMS-SB cells by sCD23, LP and vitronectin increase Jak2 
phosphorylation. Lysates were extracted from cells either stimulated with 33µM LP, 10nM 
sCD23 or 1.8nM vitronectin or without stimulation for the indicated time course and, after 
western blotting, probed with antibodies to phosphorylated Jak2 then stripped and re-probed 
with antibodies to Jak2 protein Panel a). Panel b) is the densitometric analysis for the phospho-
Jak2/Jak2 ratios demonstrated. The other Panels c)and d) are the densitometric analysis for the 
phospho-Jak2/Jak2 ratios for another blots of two individual experiments have been carried out 
in different weeks. Black bars are for LP stimulated cells, grey bars are for sCD23 stimulated 
cells and the blue bars are for vitronectin treated cells. 
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4.2.5 Either Jak2 inhibitor (AG490) or PDGF receptor 
inhibitor (AG1295) reduces both SMS-SB cell growth and 
STAT5 phosphorylation 
 
AG490 and AG1295 are synthetic compounds belonging to a large family called 
tyrphostins.  Biologically, tyrphostins are protein  tyrosine kinase (PTK) inhibitors 
which  are designed for blocking their selective target 299. In some references they are 
called Tyrphostin-490 and Tryphostin-1295.  
The chemical structure of the AG490 is N-benzyl-3,4-dihydroxybenzylidenecyanoacet-
amide. Wang et al  reported that AG490 inhibits Jak2, STAT1 and STAT3 tyrosine 
phosphorylation 300. In other context, Meydan et al showed that AG490 induces the 
programmed death of human B-precursor leukaemic cells  301. The chemical structure 
of AG1295 is 6,7-Dimethyl-2-phenylquinoxaline and it is a selective PDGF receptor 
kinase acting as a competitive inhibitor for the ATP binding site of the kinase 302.   
In order to verify whether Jak2 is a kinase of STAT5a/b or not 100µM AG490 was 
incubated with SMS-SB cells cultured in protein-free hybridoma medium for three 
hours before adding the stimuli. Panel(a) in figure 4.7 clearly shows that AG490 
reduces the cell growth stimulated by LP by more than 30% and the P value for three 
individual experiments was less than 0.05. Similar growth reduction occurs with cell 
growth stimulated by soluble CD23 with a similar outcome of the statistical analysis 
for three independent experiments. In the case of vitronectin, there is no clear growth 
stimulation and the effect of AG490 is similar to untreated cell growth.  
In the same context, AG490 strongly reduces the phosphorylation of both Jak2 and 
STAT5 in either untreated cells or cells stimulated by LP or vitronectin as shown in 
panel (c) figure 4.7.  
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The purpose for using the PDGF receptor kinase inhibitor (AG1295) is to investigate 
the possible role of PDGF receptor kinase in Jak2/STAT5 phosphorylation and also to 
examine its role in SMS-SB cell growth stimulated by different αVβ5 integrin. 
 In figure 4.7, panel (b) clearly shows that AG1295 also reduces the cell growth 
induced by either LP or soluble CD23 in which SMS-SB cells have been incubated 
with 25µM of AG1295 for three hours before proceeding to either the proliferation 
assay or cell signalling investigation by using western blotting technology. The cell 
growth stimulated by either ligand was significantly reduced by about 30% and the P 
values for three independent experiments was less than 0.05 for both ligands. 
Panel (c) in the same figure shows that AG1295 interrupts both Jak2 and STAT5 
phosphorylation. These data suggest that somehow the αVβ5 integrin might recruit 
both PDGF receptor kinase and Jak2 in order to activate STAT5 due to its binding to 
different ligands, particularly the RKC motif containing ligands.  
 
 
 103 
 
 
  
 
Figure 4.7 AG490 and AG1295 reduce SMS-SB cells  proliferation stimulated by LP , 
sCD23 and both inhibitors interrupt Jak2/STAT5 phosphorylation. Panel (a) and (b) 
SMS-SB cells (5 ×104 cells / ml in protein-free medium) were pre incubated with either 
100µM  AG490 or 25µM  AG1295 for three hours and then stimulated by either 33µM of LP, 
10nM  sCD23 or 1.8nM  vitronectin for 48hr, then processed for Alamar Blue fluorescence. ** 
P < 0.005 versus corresponding untreated control. * P < 0.05 versus corresponding cells 
stimulated with LP, • P < 0.05 versus corresponding cells stimulated with sCD23 and ** P < 
0.05 versus corresponding untreated cells). Panel (c) lysates were extracted from SMS-SB cells 
were pre incubated with either 100µM AG490 or 25µM AG1295 for three hours at 37ºC and 
5%CO2 in a humid incubator and stimulated by either 33µM LP or 1.8nM vitronectin for 5 
minutes before extraction. After western blotting, membranes were probed with antiphospho 
STAT5bY699 then stripped and re-probed with antibodies to STAT5b protein or probed with 
antiphospho Jak2Y1007/1008 then stripped and re-probed with antibodies to Jak2 protein. These 
data are representative of three independent experiments. 
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4.2.6 SMS-SB cells fail to accept control siRNA transfection 
 
RNA interference is one of the recent useful tools to knockdown any gene of interest 
selectively. Briefly, siRNA is a small double stranded RNA that undergoes a 
cleavage process by a multidomain enzyme called Dicer (DCR) in order to form an 
RNA-protein assembly which in turn down regulates the gene that has a  compatible 
sequence to the single strand  of siRNA 303. This mechanism is called RNA-
silencing 304. Normally, the RNA-silencing mechanism plays an important role in 
immune responses to viruses especially in plants and Drosophila 305, 306. In 
mammalian cells, there is no clear relation between the expression of small siRNA 
and  the interferon machinery 307. However, the RNA-silencing system plays a 
crucial role in regulating gene expression in plants, insects and mammals 308, 309.  
In molecular biology, the small interfering RNA has become one of the useful 
techniques to study either gene or protein functions by  knocking down a certain 
gene selectively 310. The strategy of using siRNA for knocking down a gene is based 
on transfecting the cells with a specific siRNA which needs an optimized 
transfection protocol, reagents and cellular conditions which are different from one 
cell type to the next 310.  
Before going forward with using siRNA for knocking down either Jak2, PDGF 
receptor or STAT5 in SMS-SB cell, a control siRNA ( fluorescein conjugated ) was 
transfected into SMS-SB cells in different concentrations to assess the transfection 
efficiency by flowcytometry. 
Figure 4.8 panel (a) clearly shows that the cell viability is affected by the 
transfection reagent. The cell viability is reduced to about 20% when incubated  24 
hours after the control siRNA transfection with 4µl of transfection reagent 
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comparing to cell viability without transfection. The P values for three independent 
experiments is less than 0.005.  
On the other hand, the transfection efficiency increases with increasing the 
transfection reagent volume figure 4.8 panel (b). However, there is a critical 
reduction in cell viability accompanied with the siRNA transfection efficiency. 
Therefore, using siRNA technology is not suitable for cell signalling study in SMS-
SB cells.  
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Figure 4.8  SMS-SB cell viability is reduced with increasing siRNA transfection 
efficiency. SMS-SB cells were transfected with control siRNA ( Fluorescein conjugated ) by 
the indicated transfection reagent volumes. Panel (a) represents the cell viability 24 hours post-
transfection. Panel (b) represents the percentage of viable transfected cells measured by a 
flowcytometer 24 hours post-transfection. * P < 0.05 , ** P < 0.005 versus corresponding 
untransfected cells. These data represent three independent experiments. 
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4.2.7 Platelet derived growth factor receptor  (PDGFRβ) and 
αVβ5 Integrin interaction study 
 
In general, integrins activate several signalling pathways in order to initiate different 
biological events in response to a wide range of ligands. Several studies over the last 
two decades have revealed that integrins are able to activate cell signalling pathways 
in  different ways such as receptor clustering,  receptor cross-linking or cytoskeleton 
proteins assembly 311, 312, 313, 314. In fibroblasts, Zemkove and colleagues have 
reported that the β subunit of  PDGF receptor forms cell surface bridges with either 
β1 or β3 integrins after stimulating  the cells with transglutaminase 315. 
The previous data suggested that the αVβ5 integrin mediates the activation of 
Jak2/STAT5 pathway via its binding with either sCD23, LP or slightly with 
vitronectin and that activation is interrupted by  either Jak2 or PDGF receptor kinase 
inhibitors. Therefore, the questions raised are how  the  αVβ5 integrin contributes to 
the Jak2/STAT5 pathway and what is the role of PDGF receptor in that event. In 
order to answer these questions an immunoprecipitation strategy was carried out to 
examine the possible link between PDGF receptor and αVβ5 integrin. 
Figure 4.9 clearly shows that the β subunit of PDGF receptor is present in the β5 
integrin immunoprecipitates of either treated or untreated cells. The middle panel of 
figure 4.9 shows that β5 integrin is also present in the  PDGF-β receptor 
immunoprecipitates. In addition, Jak2 protein was found in PDGF-β receptor 
immunoprecipitates but not with  β5 integrin as shown in the bottom panel. 
 These data give a further conformation of Jak2/STAT5 pathway activation via the  
αVβ5 integrin and might suggest that there is an association between the integrin 
and PDGF receptor complex.  
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Figure 4.9 PDGF receptor-β and αVβ5 interact. Control and stimulated lysates from SMS-
SB cells were immunoprecipitated with antibodies to PDGFR-β or αVβ5, and the separated 
precipitates probed with anti-PDGFR-β, anti-β5 or anti-Jak2 antibodies as indicated. The 
negative control is a cell lysate immunoprecipitated with non-immune IgG, while the positive 
control is a  lysate blotted directly. (These data represent one of three independent 
experiments).  
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4.3 Conclusion 
 
 
The data presented in this chapter establish that the αVβ5 integrin stimulates the 
phosphorylation of STAT5 due to its binding to either sCD23 and LP. As shown in 
figure 4.1 and 4.2, sCD23 and LP strongly activate the phosphorylation of STAT5. In 
contrast, figure 4.3 demonstrates that vitronectin does not show clear activation. 
Moreover the data shown in figure 4.4 and 4.5 indicate that both LP and sCD23 
stimulate STAT5/DNA binding and transcriptional activity with minimal activation 
shown with vitronectin. 
In addition, the data presented in figure 4.6 show that the αVβ5 integrin activates   Jak2 
phosphorylation due to its binding with either sCD23, LP or vitronectin. SMS-SB cell 
growth and Jak2 phosphorylation was blocked by using either Jak2 or PDGF receptor 
inhibitors as shown in figure 4.7. 
Interestingly, the data obtained from the immunoprecipitation strategy strongly suggest 
that there is an association between the αVβ5 integrin and the PDGF receptor which 
might influence the stimulation of the Jak2/STAT5 signalling pathway via the αVβ5 
integrin. However, further experiments need to be done to explain the nature of αVβ5 
integrin- PDGF receptor association, for example by using confocal microscopy and 
fluorescence resonance energy transfer . 
In a different context, according to Acharya et al (2009), both sCD23 and LP stimulate 
ERK1/2 phosphorylation which might be one of the key targets that might underlie the 
SMS-SB cell growth mediated by the αVβ5 integrin. Therefore, the next chapter will 
proceed to investigate the role of both sCD23 and LP in the activation of the ERK1/2 
signalling pathway and to study the effect of SDF1-α and PDGFAB on STAT5 and 
Serum response factor (SRF) transcriptional activation. Furthermore, it will contain an 
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examination of the effect of sCD23 in activating the proliferation of 697 and BAF03 
cell line models in order to study the importance of the αVβ5 integrin in promoting the 
survival and proliferation of B-cell progenitors and acute lymphocytic leukaemia cell 
line models. 
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5. αVβ5 integrin mediates the 
phosphorylation of multiple kinase 
substrates due to its binding to soluble 
CD23, LP and Vitronectin 
 
 
 
5.1 Introduction 
 
Many published studies over the last two decades have revealed that several 
signalling pathways contribute to cell proliferation and apoptosis. One of these 
pathways is the Ras/Raf/MEK/ERK cascade. Our laboratory has published that the 
sCD23-αVβ5 integrin interaction activates ERK phosphorylation 123. Therefore, the 
main aim of this chapter is to follow up on the ERK phosphorylation stimulated by 
sCD23 to look for downstream targets of phosphorylated ERK such as p90RSK 
and SRF. The other aim is to investigate the effect of either PDGF-AB or SDF1-α 
on the activation  of STAT5b and SRF  reporter vectors in SMS-SB cells. 
This chapter will include an attempt to investigate if there is a role of the αVβ5 
integrin in controlling Calpain enzymatic activity in SMS-SB cell due to integrin 
interaction with different ligands. Calpain is a calcium-dependent endopeptidase 
that plays a crucial role in activating caspase pathways in response to either 
intrinsic or extrinsic factors and also cleaves some cytoskeletal proteins that  
involved in signal transduction pathways mediated by integrins particularly β 
integrins 316, 317. Moreover, Pfaff et al have reported that Calpain cleaves β integrin 
cytoplasmic domain 318. 
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The last purpose of this chapter is to investigate the effect of sCD23-αVβ5 integrin 
interaction in activating STAT5 in two different cell lines represent different stages 
in B-cell lineage. 
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5.2 Results 
 
5.2.1 Soluble CD23, LP and vitronectin activate p90RSK at 
four residues in different trends 
 
The p90RSKs are 90KDa serine/threonine kinases which are also called ribosomal S6 
kinases. In humans, there are four isoforms of RSKs, RSK1, RSK2, RSK3 and RSK4, 
as well as  two structurally-related proteins, mitogen and stress- activated kinase-1 and 
-2 ( MSK1 and MSK2 ) 319, 320, 321. 
Several published articles show that RSKs lie downstream of the MEK/ERK pathway 
in response to different stimulants such as growth factors, cytokines and hormones 322, 
244,
 
323,
 
320
. According to Jensen et al the phosphorylation of the linker region between 
N- and C- termini is required for the kinase activation of p90RSK 324. Six different 
phosphorylation sites have been clearly identified in p90RSK, and four of them are 
located in the linker region; these are  Ser221, Thr 573, Ser 363 and Ser 380 324, 325, 326. 
In addition, Threonine 573 has been identified as the binding site for ERK1/2 325, 327. 
The p90RSK plays different biological roles as it is a growth factor- and cytokine- 
responsive cell signalling element, for instance in cell proliferation, differentiation and 
motility 328, 329, 330, 331.  
In fact, the purpose for studying p90RSK activation after stimulating the cells by 
sCD23, LP and vitronectin is to extend the earlier ERK phosphorylation studies to seek 
targets downstream of  ERK1/ERK2. 
Figure 5.1 clearly shows that p90RSK phosphorylation at Thr573  increased within 
five minutes of adding LP, and was sustained over the 20 minutes time course; a 
similar effect occurs on p90RSK at Thr359, Ser363 and Ser380. Soluble CD23  and 
vitronectin also give similar impact on these four residues but to different extents and 
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at different times during the 20 minutes experimental time course. On the other hand, 
there is a clear increase in p90RSK phosphorylation at  Thr359, Ser363 and Thr573 in 
unstimulated cells but that always came after 20 minutes of incubation at the same 
conditions.  
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Figure 5.1 Stimulation of SMS-SB cells by sCD23, LP and vitronectin increase p90RSK 
phosphorylation at different residues. Lysates were extracted from cells either stimulated by 
33µM LP, 10nM sCD23 or 1.8nM vitronectin, or without stimulation for the indicated time 
course and, after western blotting, probed with antibodies to phosphorylated p90RSK(Thr573), 
(Thr359,Ser363) or (Ser380) then stripped and re-probed with antibodies to p90RSK protein 
(Panel a). Panel b) is the densitometric analysis for the phospho-p90RSK/RSK ratios. Black 
bars are for LP stimulated cells, grey bars are for sCD23 stimulated cells and the blue bars are 
for Vitronectin treated cells. These data are representative of at least three independent 
experiments.   
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5.2.2 The MEK1/2 inhibitor U0126 inhibits the 
phosphorylation of both ERK1/2 and p90RSK modulated 
via the αVβ5 integrin 
 
 
U0126 is a MEK1/2 inhibitor initially identified as  an inhibitor of AP-1 
transactivation 258. The chemical structure of U0126 is1,4-diamino-2,3-dicyano-1,4-
bis[2-aminophenylthio]    butadiene 332.   In the last ten years U0126 has been 
broadly used in the context of studying the role of MEK/ERK pathway in many cell 
types and under many different conditions. 
According to Acharya et al 123 ERK1/2  is phosphorylated in SMS-SB cells after 30 
minutes of stimulation with sCD23 123. In this experiment, SMS-SB cells have been 
incubated with 5µM of U0126 for 30 minutes and then stimulated with either 
sCD23, LP or vitronectin for 10 minutes. In the other part of the experiment, SMS-
SB cells were either stimulated with sCD23, LP or vitronectin or without 
stimulation for 10 minutes which represents a control.  
Figure 5.2 panel (b) clearly shows that LP, sCD23 and vitronectin stimulate the 
phosphorylation of ERK1/2 at T202/Y204 and T185/Y187 after 10 minutes of the 
stimulation to different levels. This event is strikingly absent in cells pre-incubated 
with U0126. The same figure shows that U0126 strongly inhibits the 
phosphorylation of p90RSK at all four residues (Ser380, Thr 359, Ser 363 and Thr 
573) that are stimulated by the same ligands at the same time point. These data 
suggest that the phosphorylation of both ERK1/2 and p90RSK by these ligands is 
MEK-dependent. However, it is not clear yet whether the phosphorylation of 
p90RSK lies downstream of ERK1/2, which is a good fit the work reviewed in this 
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chapter, or another kinase such as ERK5. In fact, these possibilities require further 
study. 
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Figure 5.2 U0126 inhibits both ERK1/2 and p90RSK phosphorylation mediated by  
αVβ5 integrin. SMS-SB cells were pre-incubated either in presence or absence of  5µM 
U0126 for 30 minutes and  stimulated for 10 minutes by the indicated ligands or without  
stimulation as a control. After western blotting, (a) the separated proteins were probed with 
antibodies to phosphorylated p90RSKT359/S363, p90RSKT573, p90RSKS380 or with antibodies to 
p90RSK protein. Panel (b)  the separated proteins were probed with antibodies to 
phosphorylated  ERK1T202/Y204/ERK2T185/Y187 or with antibodies to ERK1/2 protein. (These 
data represent one of three independent experiments).  
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5.2.3 Neither LP nor vitronectin affects calpain enzymatic 
activity during either chronic or acute time course 
windows   
 
 
The calpain activity assay is based up on the detection of emitted light by a 
fluorimeter due to cleaving a specific calpain cleavable substrate ( Ac-LLY-AFC ). 
There are two purposes for  measuring  calpain activity in the context of the αVβ5 
integrin-mediated signaling pathways. The first aim is to investigate the role of 
calpain in cleaving cytoskeletal proteins due to stimulating SMS-SB cells by either 
LP or vitronectin and for that purpose the calpain activity was measured over a 
0,3,15,25 and 40 minutes time course. The other aim is to investigate the extrinsic 
effect of either LP or vitronectin on apoptosis pathways and for that reason the 
calpain activity was estimated within a 0, 0.5,1,2 and 4 hours time course. 
Figure 5.3 shows that there is no clear effect on calpain activity with either LP or                     
vitronectin stimulation with the exception of 20% increase following vitronectin 
stimulation at the 3 minute time point. These data suggest that the calpain system is 
not involved in cell signaling pathways mediated by αVβ5 integrin due to its 
interaction with sCD23,LP or vitronectin.   
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Figure 5.3 There is no change in Calpain activity  in SMS-SB cells stimulated by either 
LP or vitronectin within either short or long time course. SMS-SB cells were either 
stimulated by LP or Vitronectin or without stimulation for the indicated time points. Cellular 
proteins were extracted in the absence of protease inhibitors. 60µg total protein/ 85µl of 
extraction buffer were mixed with 10µl of 10x reaction buffer and 5µl of  Calpain 
substrate provided from abcam followed by an hour incubation at 37ºC in the dark. The 
reaction was measured by fluorimeter at 355nm excitation filter and 505nm emission filter. 
Panel (a) demonstrates the Calpain activity within short time course and panel (b) 
demonstrates the Calpain activity within long  time course experimented. * P < 0.05 versus 
corresponding untreated cells at the same time point. (These data represent three independent 
experiments).  
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5.2.4  Vitronectin, sCD23 and LP activate SRF-responsive 
luciferase vectors  
 
Serum response factor (SRF) is a nuclear protein that binds the Serum Response 
Element (SRE) in order to regulate the transcription of set of genes that control 
normal cell growth, apoptosis, and other cellular activities 333, 334.  Several published 
studies show that SRF forms different ternary complexes with different transcription 
factors such as Elk-1, SAP-1 and Ets-1 in order to regulate a wide range of genes 335,  
336,
 
337
. Moreover, serum stimulation strongly increases SRF transcriptional activity 
338
. The phosphorylation of SRF lies downstream of different kinases mainly ERK2, 
p90RSK and JNK  339, 340, 341, 342. 
The investigation of  the effect of sCD23,LP and vitronectin on SRF activation is to 
follow up the data that were obtained at the beginning of this chapter and in order to 
identify downstream signalling  outputs of both ERK1/2 and p90RSK. 
As shown in figure 5.4  the αVβ5 integrin ligands  clearly increase the luciferase 
activity  in SMS-SB cells which have been transiently transfected with pGL4.34 
[luc2P/SRF-RE/Hygro] vector. In this experiment, a 10% (v/v) of serum was used as a 
positive control which shows very clearly that the serum stimulates SRF activation up 
to 3-fold compared to untreated cells. These data suggest that the αVβ5 integrin 
activates the transcriptional activity of SRF via its interaction with different ligands. 
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Figure 5.4  Vitronectin, LP and sCD23 stimulate SRF responsive reporter vector. SMS-
SB cells were transiently transfected by pGL4.34[luc2P/SRF-RE/Hygro] vector. Cells 
were incubated for 48 hours at 37oC and 5% CO2 followed by adding the stimuli 1.8nM Vn 
(blue bar), 33µM LP (black bar), 10nM sCD23 (grey bar) and 10% (v/v) serum, as a positive 
control,. After 6 hours further incubation, the luciferase activity was measured by using 
luciferase substrate in a plate luminometer. (These data are for one representative of three 
independent experiments ).   
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5.2.5 SDF1-α stimulates SRF reporter vector but does not 
stimulate STAT5 reporter vector 
 
 
In the third chapter of this thesis, we have shown that SDF1-α  stimulates SMS-SB 
cell growth at 31.25nM. However, the SDF1-α stimulation was much less than the 
growth stimulated by LP, a soluble CD23 derivative, and also SDF1-α  enhances the 
LP stimulation by about 20%. Therefore, the aim of investigating the effect of SDF1-
α  in both STAT5 and SRF reporter activation is an attempt to study the link between 
growth stimulated by both sCD23 and SDF1-α in order to find out key points of that 
event. 
In figure 5.5 panel (a) SDF1-α does not show a considerable effect on STAT5 
responsive vector, while sCD23 has significantly stimulated that reporter. On the 
other hand, SDF1-α activates the SRF responsive vector but also not as much as 
sCD23 stimulation (figure 5.6 (b)). 
 In addition, SDF1-α fails to cause additional stimulation of either the STAT5 and 
SRF reporter activity when added together with sCD23. These data suggest that 
SDF1-α does not mediate STAT5 activation but it does activate SRF at a limited 
level. 
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Figure 5.5  SDF1-α stimulates SRF responsive reporter vector but not STAT5 reporter 
vector. SMS-SB cells were transiently co-transfected with (pTL-luc) and (pTL-TAD) 
STAT5b responsive vectors panel (a), or transfected with pGL4.34[luc2P/SRF-RE/Hygro] 
vector panel (b). Cells were incubated for 48 hours at 37oC and 5%CO2 followed by adding 
the stimuli; 31.25nM recombinant SDF1-α (blue bar), 10nM sCD23 (grey bar) or both 
together (black bar). After 6 hours further incubation, the luciferase activity was measured by 
using luciferase substrate in a plate illuminometer. (These data are for one representative of 
three independent experiments). 
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5.2.6 PDGF stimulates STAT5 transcriptional activity but 
does not stimulate SRF   
 
The previous data show that PDGF stimulates SMS-SB cell growth and enhances the 
cell growth stimulated by the LP, a sCD23-derived peptide. In addition, there appears 
to be an association between PDGF receptor-β and αVβ5 integrin due to its interaction 
with the specific ligands. The purpose for examining the effect of PDGF in 
stimulating the transcriptional activity of both STAT5 and SRF is to follow up the 
previous data and to find out whether STAT5 and SRF can be activated by the PDGF 
receptor. 
Figure 5.6 panel (a) shows that PDGF stimulates the transcriptional activity of STAT5 
which fits well the literature review of JAK/STAT pathway and the data shown in the 
two previous chapters. In the same panel, sCD23 shows even further stimulation 
compared to the untreated control cells. 
However, PDGF does not show a clear stimulation in activating the SRF responsive 
vector as demonstrated in panel (b), whereas sCD23 shows a highly significant 
stimulation. On the other hand, PDGF does not enhance either STAT5 or SRF 
reporter activated by sCD23. These data suggest that PDGF stimulates STAT5 
transcriptional activity to a certain extent but does not drive the activation of SRF. 
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Figure 5.6 PDGF stimulates STAT5 transcriptional activity but does not stimulate SRF. 
SMS-SB cells were transiently co-transfected with (pTL-luc) and (pTL-TAD) STAT5b 
responsive vector (panel (a)) or transfected with pGL4.34 [luc2P/SRF-RE/Hygro] vector 
(panel (b)). Cells were incubated for 48 hours at 37oC and 5% CO2 followed by adding the 
stimuli; 8.3nM PDGF-AB (blue bar), 10nM sCD23 (grey bar) or both together (black bar). 
After 6 hours further incubation, the luciferase activity was measured by using luciferase 
substrate in a plate illuminometer. (These data are for one representative of three independent 
experiments). 
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5.2.7 Soluble CD23 induces the growth of 697 and BAF03 
cell line models  
 
 
697 is a cell line derived from the bone marrow of a 12 year-old boy diagnosed with 
acute lymphocytic leukaemia (ALL) 267. The 697 cell represents the pre-B stage of 
development of B-cell in which expresses the cytoplasmic and surface µ-chains 267. 
Therefore, the 697 cells seem to represent the next developmental stage of B cell 
development compared to SMS-SB cells. 
 The other cell line to be examined is called either BAF03 or BA/F3. These cells are 
lymphoblasts derived from murine bone marrow and cannot grow without exogenous 
IL-3 supplementation 343, 266. These cells do not express IgM which is a marker for 
both immature and mature B lymphocytes 343. 
 In fact, the aim of this experiment is to ask whether the sCD23 stimulates the growth 
of these cell lines as it does with the SMS-SB cells. Figure 5.7 (panel a) clearly shows 
that 1µg/ml (40nM) of sCD23 significantly stimulates 697 cell growth up to about 
2.5-fold compared to untreated cells ( P value is less than 0.005 ).  
Similarly, 2µg/ml sCD23 stimulates the growth of the BAF03 cells up to 2-fold , 
which is also significant ( P value is less than 0.005 ) as shown in figure 5.7 (panel b). 
These results suggest that the sCD23-αvβ5 interaction stimulates the growth of 
different stages of B cell precursors.  
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Figure 5.7  sCD23  stimulates growth of 697 and BAF03 cells. Panel (a) 697 cells were 
cultured at  (5×104 cells / ml in protein-free medium supplemented by 1% (v/v) FCS) and 
stimulated  with 40nM of sCD23 for 48hr (gray bar). Panel (b) BAF03 cells were cultured at  
(5×104 cells / ml in protein-free medium supplemented by 1% (v/v) FCS) and stimulated  with 
80nM of sCD23 for 48hr (gray bar). Cells then were processed for Alamar Blue fluorescence 
followed by 24hr further incubation at the same conditions. * P < 0.005 versus corresponding 
untreated cells. (These data represent three independent experiments). 
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5.3 Conclusion 
 
 
The data presented in this Chapter show that αVβ5 integrin activates p90RSK 
phosphorylation at four different residues Ser380, Thr 359, Ser 363 and Thr 573 due 
to its binding to the extracellular matrix ligands represented by vitronectin and the 
soluble ligands such as CD23 and LP as shown in figure 5.1. The phosphorylation of 
these residues is required  for the  p90RSK kinase activation  324, 325, 326. Moreover, the 
data shown in figure 5.2 indicate that the phosphorylation of p90RSK by these ligands 
was completely blocked by the specific MEK1/2 inhibitor (U0126) which suggests 
that the activation of MEK is essential for the phosphorylation of both ERK1/2 and 
p90RSK. Although these data are consistent with several published reports it is not 
clear yet whether ERK1/2 is the kinase of the p90RSK or not which needs further 
investigations.  
The data presented in figure 5.5 show that SDF1-α activates the SRF reporter 
construct but not the STAT5 construct. In contrast, PDGFAB stimulates the STAT5 
transcriptional activity but not the SRF. These findings may suggest that PDGFAB 
involves the Jak2/STAT5 pathway while SDF1-α involves the 
MEK/ERK/p90RSK/SRF signalling pathway, in order to stimulate SMS-SB 
proliferation. 
Finally, soluble CD23 activates the growth of both 697 and BAF03 cells at different 
concentrations 40nM and 80nM respectively which indicates that the sCD23-αvβ5 
interaction might be important in inducing the growth and survival in ALL B cells.  
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6 Discussion 
 
 
The data presented in this thesis show that the αVβ5 integrin, PDGF receptor and 
CXCR4 are expressed on SMS-SB cells. These receptors stimulate cell growth to 
characteristic levels in response to different ligands. As shown in the first results 
Chapter, the αVβ5 integrin mediates SMS-SB cell growth when it binds either LP or 
sCD23 which both contain the RKC motif. In addition, both SDF1-α and PDGF-AB 
stimulate SMS-SB proliferation to a limited extent. 
Moreover, sCD23, LP and vitronectin induce the JAK2/STAT5b signalling pathway 
to different levels and at different times over a 20 minutes time course. In addition, 
the third Chapter of this thesis showed that sCD23, LP and vitronectin stimulate the 
phosphorylation of ERK1/2 and p90RSK, and induce SRF transcriptional activity in 
SMS-SB cells. 
 
6.1 SMS-SB cell phenotypic characterization 
 
SMS-SB is a cell line  derived from a female patient  in the leukemic phase of 
lymphocytic leukaemia 265.  Smith and colleagues found that these cells  express 
cytoplasmic µ-chain 265. The data shown in the first results Chapter of this thesis show 
that these cells express CD19 which is the major marker of B-cell progenitors. 
However, these cells do not express CD34  which is a determinant of the  early stage 
of  antigen- independent phase of B-cell development. In addition, the SMS-SB cell 
does not express CD5, a marker of B-cells in both human fetal and postnatal lymphoid 
tissues 276. Furthermore, these cells do not express some pre-B cell determinants such 
as CD10 and µ-chain at the cell surface.  The data shown in this thesis and the data 
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presented by Smith et al suggest that the SMS-SB cell probably represents the stage 
between pro-B and pre-B cells. Figure 6.1 demonstrates the possible stage of SMS-SB 
cells within the B-cell lineage scheme. Figure 3.1 shows that SMS-SB cells express 
αVβ5 integrin, but not αVβ3 integrin, and also express the PDGF receptor and 
CXCR4: expression of these markers is consistent with data from other reports 265, 123 
. 
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Figure 6.1 B-cell development stages in Bone Marrow. SMS-SB cell represents the area 
between pro-B and pre-B cell according to the data shown in the third Chapter and  Smith RG 
et al  265. 
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  6.2  SMS-SB cell growth mediated via different soluble 
ligands 
 
The proliferation data presented in Chapter 3 show that SMS-SB cell growth is 
increased in response to different stimuli. This growth increase is different from one 
ligand to the other and it is dose-dependent. 
In this regard, figure 3.2 showed that SMS-SB cell growth is density-dependent which 
is compatible with Tsai et al who showed that SMS-SB cells express PDGF as an 
autocrine growth factor 271. The fact that these cells fail to sustain their own growth at 
low density which might indicates that the expression of the PDGF in these cells 
requires an extra communication between the cells such as cell-cell adhesion and the 
αVβ5 integrin might play a role in that kind of adhesion. This hypothesis needs 
further work such as knocking the αVβ5 integrin down using Lentiviral small hairpin 
RNA (shRNA) followed by a cell density-dependent growth study. In addition, the 
cell density growth experiments in this study were assessed by two different methods; 
Alamar blue and tritiated thymidine incorporation, and there is a robust signal-to-
noise ratio in both of them which means either of these methods could be used for 
mammalian cell proliferation studies. 
Stimulation of SMS-SB cells using either sCD23 or LP, (the RKC motif-containing 
ligands) which act via the αVβ5 integrin induced significant growth increase. LP 
stimulates SMS-SB cell growth at the concentrations of 33 and 66µM and sCD23 
shows a similar effect. Both LP- and sCD23-driven growth stimulation seems to be 
dose-dependent as shown in figure 3.3. On the other hand, a matrix ligand containing 
the RGD motif, vitronectin, does not stimulate the cell growth, which suggests that 
the αVβ5 integrin stimulates SMS-SB when it binds RKC motif-containing ligands 
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but not RGD motif-containing ligands. These data are consistent with results  
published by both Acharya et al 123 and Borland et al 95. In the same context, figure 
3.4 and figure 3.5 clearly demonstrated that either PDFGAB or SDF1-α induces SMS-
SB cell growth to modest levels, and both ligands significantly enhance the cell 
growth stimulated by LP. These data are also compatible with the data shown by 
Acharya et al 123 and Tsai et al 271. However, more investigations should be done to 
determine whether that significant proliferative response to the different ligands used 
in this study, is specific for SMS-SB cells and other types of leukaemia as shown in 
figure 5.7 or important at a specific stage of B-cell development. One useful approach 
is studying the effect of these ligands and the role of the αVβ5 integrin in normal B-
cell precursors. 
 
6.3 Different kinase substrates stimulated by either 
sCD23 or LP 
 
The antibody array data clearly showed that multiple signalling pathways might 
control how the αVβ5 integrin mediates the growth increase stimulated by sCD23. A 
surprising observation presented in figure 3.6 is that both LP and sCD23 strongly 
induce the phosphorylation of STAT5 at tyrosine 699, and moderately on STAT2 at 
tyrosine 689. This seems to be unusual in that the αVβ5 integrin rarely mediates the 
phosphorylation of any STAT family member according to the work reviewed in the 
first Chapter of this thesis. In addition, this event was consistent over the 20 minute 
time course experimented. The other observation on the array is that both LP and 
sCD23 stimulate the phosphorylation of c-Src at tyrosine 419. This event appeared 
after 5 minutes of LP stimulation and was increased gradually over the 20 minutes of 
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sCD23 stimulation. Similar trends are observed with c-yes which was phosphorylated 
at tyrosine 426. c-yes is a member of Src family kinases and both c-yes and c-Src can 
regulate different signalling pathways involved in cell growth, motility, survival and 
differentiation 344, 345. Therefore, the phosphorylation of c-yes with the same trends of 
phosphorylation of c-Src by both ligands might represent a good technical control. 
Both LP and sCD23 activate the phosphorylation of the AMP-activated protein kinase 
α2 (AMPKα2) at threonine 172, a protein that plays a crucial role in ATP generating 
mechanisms and protein synthesis 346, 347. In fact, the phosphorylation of AMPKα2 in 
response to both ligands might be involved in energy supply for the cell growth 
stimulated by these ligands or might be involved in a protein synthesis regulation; this 
merits further investigations.   
6.4 STAT5b activation  
 
 
In normal conditions, IL-7 plays an essential role in early B-cell development via 
activating STAT5, and STAT5a/b is also required for survival of CD8+ T cells 226, 227.  
In addition, STAT5 controls Bcl-6 expression in germinal centre B cells which leads 
to self-renewal and differentiation of  human memory B cells 228. However, STAT1, 
STAT3 and STAT5 were found to be activated in response to different cytokines and 
growth factors in several leukaemic cell line models, particularly in  early B-precursor 
acute lymphoblastic leukaemia and chronic myeloid leukaemia and this activation 
mainly lies downstream of JAK2 196, 197, 200. Moreover, Catlett-Falcone et al showed 
that constitutive STAT3 signalling activation underlies  the apoptosis resistance of 
multiple myeloma  cells in which the activated STAT3 in turn activates Bcl-2 and 
Bcl-xL expression 204.  
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The data illustrated in this thesis show that the αVβ5 integrin mediates the 
phosphorylation and activation of STAT5b due to binding specific ligands. As shown 
in figures 4.1 and 4.2, both sCD23 and LP stimulate STAT5 phosphorylation at 
tyrosine 699 over the 20 minutes time course while vitronectin does not. The 
phosphorylation of STAT5 at this specific residue is required for STAT5 activation 
208,
 
213
.  These data validate the results obtained by the antibody array and also 
highlight another difference between the RGD- and RKC- containing stimuli. In 
addition, the phosphorylated STAT5 has DNA binding and transcriptional activity as 
shown in figures 4.4 and 4.5. These figures demonstrated that LP and sCD23 activate 
cell growth and STAT5 to similar extents which suggest that STAT5 plays a key role 
in these stimulations. In the case of vitronectin, this ligand shows a minimal activation 
of STAT5 which also fits well with the proliferation data presented in Chapter 3. 
 In fact, several studies have shown that STAT5 regulates a range of genes in different 
cell types. In terms of SMS-SB cell growth stimulation, there are some candidate 
genes that might be regulated by STAT5 such as Bcl-xL in the context of anti-
apoptotic mechanisms, cyclin D
 or STAT5 might regulate the expression of PDGF, the 
autocrine factor
 that might underlie the cell density growth dependence. Therefore, it 
would be very interesting to identify the STAT5 target genes in response to soluble 
CD23- αvβ5 integrin interaction. In this regard, a chromatin immunoprecipitation 
strategy (Chip-Sequencing) is one useful technique which uses a genome sequencer to 
provide the sequences of DNA fragments that have been immunoprecipitated with an 
antibody against a target transcription factor such as STAT5 348. In fact, the Chip-
Sequencing technique would identify a primary gene network which will 
subsequently need a further investigation to study the effect of the CD23- αvβ5 
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integrin interaction on the regulation of the candidate genes in the network. 
Nowadays, DNA microarray technology is one of very common method that is used 
to study the gene expression levels. This technique might be useful as a follow-up to 
Chip-Sequencing data together with a further independent gene expression estimation  
such as quantitative real time polymerase chain reaction (qRT-PCR) 349, 350.  
 
6.5 The role of JAK2  
 
 
The JAK protein family members are the main kinases for STATs 189, 190. The 
JAK2/STAT5 signalling pathway was identified in different haematopoietic 
malignant cell line models, particularly in early B-precursor acute lymphoblastic 
leukaemia in which the cells express TEL-Jak2 fusions as a product of  
t(9;12)(p24;p13) translocations, and in chronic myeloid leukaemia with additional 
translocations t(9;15;12)(p24;p15;p13) 196, 197. In both cases the transcription factor 
Tel is fused to the JH1 domain of Jak2 and consequently activates STAT1 and STAT5 
198,
 
199,
 
200
.  
In this regard, the data shown in the fourth Chapter of this thesis clearly demonstrate 
that both LP and sCD23 stimulate the phosphorylation of JAK2 at tyrosine 1007/1008 
with similar trend of STAT5 activation as shown in figure 4.6. The phosphorylation of 
Jak2 at these sites is potentially required for Jak2 auto- or trans-phosphorylation and 
for Jak2 kinase reactions 298. Moreover, both STAT5 and JAK2 inductions were 
knocked down by using either PDGF receptor inhibitor (AG1295) or JAK2 inhibitor 
(AG490) and both inhibitors reduce the cell growth in the absence or presence of 
stimulation as shown in figure 4.7. Although there is a concern about the selectivity of 
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these inhibitors, these accumulated data suggest that the STAT5 activation mediated 
via the αVβ5 integrin might be JAK2 dependent and that also need more investigation 
on the role of either Jak1, Jak3 or Tyk2 in that event 351,352,353. Unfortunately, one of 
the obstacles that been faced in this project is the difficulty of transfecting SMS-SB 
cell with siRNA which is usual in all lymphocytes, however, it would be good to try 
using the Lentiviral shRNA to study STAT5 phosphorylation in either Jak2 or PDGF 
receptor knocked out SMS-SB cells.  
 
 
  6.6 PDGF receptor-αVβ5 integrin cross linking 
 
 
Several studies over the last two decades have revealed that integrins are able to 
mediate cell signalling pathways in  different ways such as receptor clustering,  
receptor cross-linking or cytoskeleton protein dynamics 311, 312, 313, 314. 
Zemkove and colleagues have reported that the β subunit of  PDGF receptor forms 
cell surface bridges with either β1 or β3 integrins after stimulating fibroblasts with 
transglutaminase 315. Sundberg and Rubin have published that the stimulation of  β1 
integrin activates the phosphorylation of the PDGF receptor 63. 
 The data presented in figure 4.9 show that the β subunit of PDGF receptor is co-
immunoprecipitated with the β5 integrin after stimulating SMS-SB cells with LP, 
sCD23 or vitronectin; the β5 integrin is present in the PDGF receptor 
immunoprecipitates. Therefore, these data are consistent with results published 
about the association of PDGF receptor with other integrins. Furthermore, JAK2 is 
present in the PDGF-receptor  immunoprecipitates but not in the β5 integrin 
precipitates which is also consistent with results of Ihle et al 185, 186 . Although these 
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data do not explain the nature of this interaction, whether it is a physical cross-link 
or due to receptor clustering, there are several useful techniques that can elucidate 
the nature of this association such as confocal microscopy and fluorescence 
resonance energy transfer. Moreover, investigating the interaction between the 
αvβ5 integrin and the PDGF receptor in different B-cell malignant cell lines would 
be valuable to understand and disrupt the proliferation mechanism and anti-
apoptosis.  
In conclusion, there are different scenarios to explain how the αVβ5 integrin 
mediates the activation of the JAK2/STAT5 signalling pathway and figure 6.2 
summarizes one of these possible scenarios. 
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Figure 6.2 Scenario for αVβ5 -mediated STAT5 activation. The binding of  the αVβ5 
integrin to the stimuli (LP or sCD23) induces PDGF receptor- αVβ5 integrin association 
and that propagates JAK2/STAT5  pathway. The activated STAT5 in turn regulates the 
transcription of certain genes that might be related to either cell growth or apoptosis.  
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6.7 The phosphorylation of ERK and p90RSK 
 
 
As mentioned in the introduction, activation of ERK1/2 was found to be linked with 
several biological actions such as cell growth, survival and proliferation in different 
cell types. Moreover, there is some evidence that the activation of ERK is required for  
cell cycle progression, and more precisely for cell transition from G1 phase into S 
phase, which means that the activated ERK is also required for DNA synthesis 234, 235, 
236
. 
In haematopoiesis, the Ras/Raf/MEK/ERK cascade plays different roles depending on 
the cell type and the maturation step it is involved in. The activation of MEK/ERK 
signaling by stem cell factor (SCF) stimulates  haematopoietic stem cell proliferation 
252
. Furthermore, the activation of the MEK/ERK pathway as a downstream effecter 
of cytokine receptors is involved in different  maturation steps in both lymphoid and 
myeloid lineages 253, 254. On the other hand,  activated ERK was found in about 75% 
of AML cases in a study conducted by  Ricciardi and his colleagues 255. In addition, 
increased ERK1/2 seems to be a significant indicator for both B-ALL  and T-ALL 
patients 256, 257. In the same context, the MEK inhibitor U0126 reduces growth of 
either AML or CML cell lines 258, 259. 
 In terms of SMS-SB cells, Acharya and her colleagues have shown that sCD23 
activates the phosphorylation of ERK1/2 and that this event was enhanced when cells 
were co-stimulated with SDF1-α. The data illustrated in figure 5.2 confirmed that 
sCD23 and LP stimulate the phosphorylation of ERK1/2 and that is inhibited by the 
MEK inhibitor U0126; this might mean that the phosphorylation of ERK1/2 is MEK 
dependent and that also is compatible with the work reviewed in this study. 
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Several studies have shown that RSKs lie downstream of the MEK/ERK pathway as a 
response to different stimulants such as growth factors, cytokines and hormones 322, 
244,
 
323,
 
320
. There are six different phosphorylation sites that have been clearly 
identified in p90RSK, and  four of them are located in the linker region between the 
N- and C-terminal domains (Ser 221, Thr 359, Ser 363 and Ser 380); the 
phosphorylation of this region  has been shown to be required for the activity of the 
p90 RSK 324, 325, 326. In addition, Threonine 573 has been identified as the binding site 
for ERK1/2 325, 327. The p90RSK plays different biological roles as it is a growth 
factor- and cytokine-responsive cell signalling element in cell proliferation, 
differentiation and motility 328, 329, 330, 331. In the SMS-SB model, either sCD23, LP or 
vitronectin activates the phosphorylation of p90RSK at four different residues             
( Ser380, Thr 359, Ser 363 and Thr 573 ),  with different trends and levels as clearly 
shown in figure 5.1. In addition, figure 5.2 shows that the MEK inhibitor U0126 
completely inhibits p90RSK phosphorylation with either ligand. However, it is not 
clear yet whether the phosphorylation of p90RSK is via ERK1/2, via MEK directly or 
other MEK dependent kinase such as ERK5, as published by Pearson et al 354.These 
data raised several questions about the role of  p90RSK in the context of SMS-SB cell 
growth stimulated by the αvβ5 integrin. It would be very interesting to investigate the 
role of p90RSK in Bad phosphorylation and anti-apoptotic action, and to examine the 
link between p90RSK and other possible downstream targets such as SRF, c-Fos and 
c-Jun using either Lentiviral shRNA or p90RSK inhibitors.   
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6.8 The activation of SRF  
 
 
Serum response factor (SRF) regulates the transcription of sets of genes that regulate 
normal cell growth, apoptosis, and other cellular activities 333, 334. SRF forms distinct 
ternary complexes with different transcription factors such as Elk-1, SAP-1 and Ets-1 
in order to regulate a wide range of genes 335,  336, 337. Moreover, serum stimulation 
strongly increases SRF transcriptional activity 338. The phosphorylation of SRF lies 
down stream of different kinases, mainly ERK2, p90RSK and JNK  339, 340, 341, 342. 
The SRF transcriptional activity study presented in Chapter 5 shows that the αVβ5 
integrin activates SRF to drive a reporter gene construct in SMS-SB cells transiently 
transfected with that vector. Figure 5.4 shows a significant activation increase after 
stimulating the cells with vitronectin, LP or sCD23, as well as with serum stimulation, 
compared to unstimulated cells. The data for ERK1/2 and p90RSK activation, in the 
presence or absence of U0126, and the SRF reporter results raised several questions 
drawing the complexity of signalling downstream of αVβ5 integrin, and these 
questions are summarized in figure 6.3.  
Therefore, further work needs to be done to determine whether SRF lies downstream 
of MEK/ERK1/2 and possibly p90RSK. In addition, it would be promising to 
investigate which possible proteins form a ternary complex with SRF by using a co-
immunoprecipitation technique. Furthermore, it is not clear yet what kind of link 
exists between the activation of c-Src, ERK1/2, p90RSK, SRF, STAT5 and JAK2.   
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Figure 6.3 The activation of ERK1/2, p90RSK, SRF and STAT5 leaves many question 
marks in order to understand how the sCD23-αVβ5 integrin interaction sustains the 
SMS-SB cell growth. 
  
 
 143 
6.9 Calpain activity study  
 
 
Both Calpains, µ and m are cytoplasmic cysteine proteases that play several 
biological roles in cell mobility and embryonic development due to cleaving 
cytoskeletal proteins 261, 262. In addition, both µ and m Calpains play different roles in 
cell signaling and apoptosis via cleaving caspase-7, -8, -9 and caspase-3 or via 
activating caspase activators such as APAF-1 and cytochrome C  263, 264. 
The data presented in figure 5.3 clearly show that there is no clear effect on  calpain 
activity following stimulation of  the αVβ5 integrin with either LP or vitronectin for a 
short time course (0-40 minutes) or also for along time course (0.5-4 hours). 
However, these data are not enough to say that there is no caspase involvement after 
stimulating the αVβ5 integrin with its specific ligands. Moreover, changing the 
substrate used in this experiment (AC-LLY-AFC) with other substrate such as Suc-
LLVY-aminoluciferin or (EDANS)-Glu-Pro-Leu-Phe-Ala-Glu-Arg-Lys-(DABCYL) 
might give different outcomes and lead to different conclusion. 
 
 
6.10 The activation of STAT5 and SRF by either SDF1-α 
or PDGF-AB  
 
 
SDF1 plays an essential  role in haematopoietic cell maturation, survival and 
proliferation 135. In addition, in various cell types including B cell precursors, SDF1 
increases the intracellular calcium levels via ligation of CXCR4 136, 137. This ligation 
also leads to the activation of phosphatidylinositol 3 – kinases (PI3K) and 
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phosphorylation of MEK and ERK as a consequence of phosphorylation of focal 
adhesion complexes 138. Moreover, SDF1 stimulates the Jak/STAT pathway 139. On 
the other hand, SDF1 is thought to play different pathological roles such as HIV 
infection enhancement, tumour growth, inflammation and angiogenesis 140, 141, 142. In 
terms of leukaemias, CXCR4 is highly expressed in B- chronic lymphocytic 
leukaemia cells which enhances their response to SDF1 143. Meanwhile, the 
migration, cellular adhesion and survival of  different acute lymphocytic leukaemia 
cell lines are enhanced in the presence of  SDF1 144, 145. However, the data presented 
in figure 5.5 clearly show that SDF1-α on its own significantly simulates the 
transcriptional activity of SRF but does not stimulate STAT5. These data are 
consistent with the work reviewed above and the proliferation data shown in the third 
Chapter of this thesis. 
In a wider context,  several studies have shown that the PDGFAB induces cellular 
proliferation, migration and differentiation via the RAS/MAPK pathway and 
promotes cell survival through the PI3K/Akt pathway 164, 163. In addition, PDGF 
induces the activation of both STAT1 and STAT3 via the phosphorylation of  JAK 
proteins in fibroblasts 165, 166. Moreover, PDGFAB activates STAT5 in different types 
of leukaemia such as AML and CML  168, 169, 170. 
The data illustrated in figure 5.6 show that STAT5 transcriptional activity is 
significantly induced by PDGFAB whereas there is no effect on SRF activity. These 
data strongly support the proliferation data presented in Chapter three and are 
consistent with the work reviewed in this thesis. In contrast, both stimuli do not 
provide any further stimulation to the vectors beyond that induced by sCD23.  
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To conclude, SDF1-α activates SRF but does not activate STAT5 while PDGFAB 
activates STAT5 but does not activate SRF and that probably means each stimuli 
plays its role in a different way. Similarly, it would be interesting to identify which 
genes might be regulated by STAT5 in response to PDGFAB and to compare these 
genes with the set of genes regulated by STAT5 in response to either sCD23 or 
vitronectin. In addition, using qRT-PCR might give another comparison study on 
candidate gene expression levels in response to these ligands. In terms of SDF1, 
further experiments need to be done to examine the effect of SDF1 in promoting the 
phosphorylation of p90RSK and other ERK1/2 downstream targets such as c-Fos. 
 
 
6.11 The growth of 697 and BAF03 cells with soluble 
CD23 stimulations 
 
The data illustrated in Chapter 5 (figure 5.7) demonstrates that soluble CD23 
significantly increases the 697 cell growth at the concentration of 40nM, and also 
stimulates the proliferation of murine transformed cells (BAF03) at 80nM. Acharya 
and colleagues 123 have shown that soluble CD23 stimulated the proliferation of Blin-
1 cells, a pre-B cell line model extracted from  the bone marrow of a 11-year old boy 
with ALL. Moreover, they have shown that soluble CD23-derived peptide (LP) 
stimulates the RS4;11 cell growth which is another ALL cell line model. These data, 
together with the results presented previously, might suggest that soluble CD23 
underlies the proliferation of several acute lymphocytic leukaemia cells from different 
origins. However, the data shown previously leave some challenging questions about 
the cell signalling pathways that are involved in each cell line model due to the αVβ5 
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integrin-sCD23 interaction, especially JAK2/STAT5, MEK/ERK1/2, p90RSK and 
SRF, and also about the role of sCD23 in normal pre-B cell growth and maturation.  
 
6.12 Conclusion 
 
This study has attempted to understand how the αVβ5 integrin mediates SMS-SB cell 
growth due to its binding to the model soluble ligands represented by the soluble CD23 
and LP (a synthetic peptide derived from soluble CD23). The data presented in this 
thesis can be summarized as the following: 
• The αVβ5 integrin promotes SMS-SB proliferation after binding to sCD23 
and LP, which both contain an RKC motif, while there is no proliferation after 
vitronectin binds via the RGD motif. 
• Both SDF1 and PDGF stimulate SMS-SB growth weakly, and enhance 
growth promoted by LP. 
• Both sCD23 and LP stimulate the phosphorylation of  different kinase 
substrates including STAT5a/b and STAT2. 
• Stat5B phosphorylation is induced by sCD23 or LP, and slightly by 
vitronectin. 
• sCD23 and LP strongly stimulate Stat5 DNA binding and transcriptional 
activity, but vitronectin causes minimal activation. 
• αVβ5 integrin and PDGF receptor are co-immunoprecipitated from SMS-
SB cells, and Jak2 is co-immunoprecipitated with PDGF receptor but not 
αVβ5. 
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• SMS-SB cell proliferation and Phosphorylation of Stat5b are clearly 
reduced by both Jak2 kinase inhibitor (AG490) and PDGF receptor kinase 
inhibitor (AG1295). 
• Furthermore CD23, LP and vitronectin promote the phosphorylation of 
MAPK, p90RSK and induce SRF transcriptional activity. 
• Soluble CD23 promotes the growth of 697 and BAF03 cell lines. 
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